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In Colorectal cancer (CRC) genetic and epigenetic alterations are tightly connected, 
although these interactions on the patient’s outcome are not clearly understood. 
A peculiar subclass of sporadic CRC tumors, is characterized by Microsatellite 
instability (MSI), due to hyper-methylated promoter of MHL1 gene and subsequent 
inactivation of the mismatch repair (MMR) mechanism, and the hypermethylation 
of CpG islands phenotype (CIMP), mediated by the hyper-methylation of promoter 
regions of several tumor suppressor genes (TSGs). This subclass carries a good 
prognosis and presents an inverse correlation with genomic and chromosome 
instability (CIN), together with a higher levels of DNA methylation at global level, 
compared to other CRCs. Among the epigenetic alterations, DNA methylation and 
histone modifications rearrangements are extremely important steps during 
tumorigenesis. UHRF1 is a key master epigenetic regulator that couples the 
maintenance of DNA methylation through the cell cycle with the histone-
modification pattern. It monoubiquitinates H3K18/23 enabling the correct 
localization and activation of DNMT1 on the specific sites. UHRF1 is overexpressed 
in several cancer types mediating the hypermethylation of promoter regions of the 
TSGs and coordinating their heterochromatic silencing. 
Relying on the idea that UHRF1 could play a crucial role in the modulation of DNA 
methylation changes, the overall aim of this PhD thesis was to evaluate the role of 
UHRF1 in the coordination of DNA methylation and histone post-translational 
modifications both at genome-wide and at locus specific level in CRCs. 
Unexpectedly, we found that in CRC tissues UHRF1 was higher in tumors with 
microsatellite instability (MSI CRC), which have a better prognosis, compared to the 
stable ones (MSS CRC). MSI tumors were also characterized by higher levels of DNA 
methylation compared to the MSS. The UHRF1 knock-down in a MSI CRC cell line 
(RKO cells) induced an overall decrease in DNA methylation (RRB-seq analysis, 
pyrosequencing and MS-MLPA) both at global level and at gene promoters without 
affecting DNMTs levels, as observed by WB and RNA-seq analysis. ChIP experiments 
showed that UHRF1 depletion reduces DNMT1 binding to both repetitive elements 
(LINE-1) and specific gene promoters (MLH1, CDH1), decreasing H3K9me3 and 
increasing H3K4me3 on those hypo-methylated loci. RNA-seq data analysis showed 
that UHRF1 loss interferes with several important pathways, among others cell cycle, 
growth and proliferation. SILAC LC-MS/MS analysis showed that in RKO cells, UHRF1 
loss decreases the overall presence of H3K23ub (  30%) and H3K18ub (  8%).  
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These results, together with the published findings, led us to hypothesize a model in 
which the loss of UHRF1 directly impairs the DNA methylation maintenance by 
reducing H3K18/K23ub and consequently DNMT1 activity and, indirectly, impairs the 
binding of Suv39H1, the histone methyl transferase (HMT) responsible for H3K9me3, 
to both genome-wide and promoter specific loci. These changes led to a severe 
chromatin rearrangement of heterochromatic signatures toward a more open and 
transcriptionally accessible structure, probably due to the disruption of the axis 
UHRF1-H3ub-DNMT1-HMTs. Our molecular data, together with the analysis 
performed on CRC samples, led us to speculate that the better prognosis correlated 
with MSI-CRC model, could reside in the UHRF1-high levels that result in a sort of 
protective condition for the genome integrity, maintaining the global DNA 
methylation level closer to the normal mucosae, and probably counteracting the 












1.1. Colorectal Cancer (CRC) 
1.1.1. Epidemiology and risk factors of CRC 
Colorectal cancer (CRC) is the third most common cancer in men (746,000 cases, 
10.0% of the total, after lung and prostate cancers), and the second in women 
(614,000 cases, 9.2% of the total, after breast cancer) worldwide. Almost 55% of the 
CRCs cases occur in more developed regions, and represent respectively the fourth 
leading cause of cancer death in men, and the third in women. However, the 
mortality is considerably lower (694,000 deaths in both sexes) compared to totality 
of cancer deaths (8.5% of the total) with the peculiarity of a variable rate in cancer 
mortality, from highest in Central and Eastern Europe (20.3 per 100,000 for men, 
11.7 per 100,000 for women), to lowest in Western Africa (3.5 and 3.0, respectively) 
[Ferlay J., et al.; Int. J Cancer., 2015]. 
CRCs in Italy has increased from 18,000 new cases per year in 1990 to 25,000 new 
cases per year in the end of 90’s, with a relative 5-years survival rate assessed around 
40%-50% [Capocaccia R, et al.; Int J Epidemiol, 1997]. Between 2003-2007, the 
Istituto Superiore di Sanita’ established a national health program regarding the CRC 
screening using the fecal occult blood test (FOBT), that resulted effective in reducing 
cause-specific mortality. Moreover, although it detects pre-cancerous adenomas, 
the screening with immunochemical FOBT (FIT) leads to a decrease in the CRC 
incidence and mortality [Giorgi Rossi P, et al.; The American Journal of 
Gastroenterology, 2015]. 
 
The probability of suffering from CRC is about 4%–5%. The most affected anatomic 
parts of Colon are the Sigmoid (25%) and the Rectum (39%) sections (Figure 1.1). 
The developing risk of CRC is associated with personal predisposing features or 
habits such as age, chronic disease history and lifestyle [Mármol I; et al.; Int. J. Mol. 
Sci., 2017]: 
- age; the CRC incidence increases proportionally with the individual age; early 
development of CRC is general related to inherited cancers; 
- chronic disease history; chronic inflammation mechanism, such as Crohn's 
bowel syndrome or ulcerative colitis can induce colonic carcinogenesis; in this 
context, the gut microbiota and dysbiosis situations have a relevant role;  
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- lifestyle; smoking, environmental factors (such as pollution), and unbalanced 
diets (rich in fat and protein, and poor in fiber and fruit) predispose to colon 
tumor development; 
- personal predisposing features; familial or inherited aberrant alterations of 
genetic and/or epigenetic factors, i.e. familial adenomatous polyposis (FAP), 
hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome, 
Hamartomatous Polyposis Syndromes, and Familial CRC without identifiable 
gene mutations [Stoffel EM, et al.; Clin Gastroenterol Hepatol. 2014]. 
 
  
Figure 1.1. Percentages of the relative tumor onset in the different anatomic trait of large intestine. Sigmoid and 
Rectum show the highest percentage of tumor onset, respectively 25% and 39%. The image is adapted from “Dionigi, 
Basi teoriche e Chirurgia generale - Chirurgia specialistica, 4ª ed., Padova, Elsevier Masson, 2006”. 
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1.1.2. Pathogenesis and classification of CRC 
The CRC is a multistep cancer, that involves several molecular pathways leading to 
genomic and epigenomic instability. Mutations and/or epigenetic alterations can 
target oncogenes, tumor suppressor genes (TSGs) and genes related to DNA repair 
mechanisms [Mármol I; et al.; Int. J. Mol. Sci., 2017]. 
 
Etiological classification 
From an etiological point of view, colorectal carcinomas can be classified as sporadic 
(70%), inherited (5%) and familial (25%) among all cases, in relation to the origin of 
the mutation/epigenetic alteration. 
Sporadic cancers derived from point mutations that can target different 
heterogeneous genes [Fearon ER and Vogelstein B; Cell, 1990]. Generally, in 
approximately 70% of the CRC with point mutations, the first mutation occurs in the 
tumor suppressor gene APC (adenomatous polyposis coli), that sustains the 
formation of non-malignant adenomas (polyps). Upon further mutations in KRAS, 
TP53 and DCC genes, these polyps tend to be promoted to a malignant carcinoma 
[Fearon ER and Vogelstein B; Cell, 1990]. 
Inherited cancers are caused by hereditary mutations. The mutated gene are 
affected in one of the alleles, and a subsequent point mutation in the other allele 
could promote the onset of the tumor. The hereditary cancers are further classified 
in two groups, called polyposis and non-polyposis forms. Polyposis variant is mainly 
represented by familial adenomatous polyposis (FAP), characterized by the inherited 
mutation of APC gene, that promotes the formation of multiple potentially 
malignant polyps in the colon [Lynch HT, and de la Chapelle A; N. Engl. J. Med., 2003]. 
On the other side, non-polyposis forms are related to mutations in DNA repair 
mechanisms. The main form of hereditary non-polyposis colorectal cancer (HNPCC) 
is Lynch syndrome, arisen from inherited mutations in one of the alleles coding for 
DNA repair proteins (e.g. MSH2, MLH1, MLH6, PMS1 and PMS2). Lynch Syndrome is 
the most common among the inherited cancer syndromes and can be found in 2–4% 
of all CRC cases [Hampel H, et al.; J Clin Oncol., 2008] [Umar A, et al.; J. Natl. Cancer 
Inst., 2004]. 
Familial colorectal cancers, approximately 25% of all CRC cases, include patients with 
a strong familial history of cancer and/or CRC diagnosis at a young age. However, the 
tests of inherited mutation, in genes known as CRC-related, cannot meet clinical 
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criteria for any of the hereditary CRC syndromes. Although these familial CRCs are 
not included in any inherited cancer variant, and their etiology remains unclear, 
exhaustive examinations of whole genome and epigenome, by next generation 
sequencing (NGS) techniques, might shed light on this significant fee of CRCs [Stoffel 
EM, et al.; Clin Gastroenterol Hepatol. 2014].  
Figure 1.2. Molecular pathways involved in colorectal carcinogenesis. Mutations or epigenetic aberrations affect genes 
(and related encoded proteins) involved in WNT (orange), EGFR/MAPK/PI3K (green), TGF-β/SMAD (blue) or DNA 




From a molecular point of view, colorectal carcinomas can be classified in three 
types, named chromosomal instability (CIN), microsatellite instability (MSI) and CpG 
island methylator phenotype (CIMP), relying on the pathogenetic-molecular 
mechanisms that lead to genomic and epigenomic instability [Ogino S, and Goel A; J. 
Mol. Diagn., 2008]. These pathogenic mechanisms can target oncogenes, TSGs and 
genes related to DNA repair mechanisms (e.g. MLH1, MSH2, MSH6, PMS1 and 
PMS2), by mutation in common genes (e.g. APC, TP53, c-MYC, KRAS, BRAF, PIK3CA, 
PTEN, SMAD2/SMAD4), by epigenetic alteration (i.e. promoter hyper-methylation or 
chromatin silencing), and by chromosomal changes and translocations (i.e. 
aneuploidy and LOH), affecting important pathways such as WNT, MAPK/PI3K, TGF-
β and TP53 (Figure 1.2) [Mármol I; et al.; Int. J. Mol. Sci., 2017]. 
 
The chromosomal instability (CIN) is the most common type of genomic instability 
observed in colon cancer, representing up to 80%-85% of all CRC cases. The hallmark 
of CIN is the imbalances in the number of chromosomes, that lead to aneuploidy and 
loss of heterozygosity (LOH) [Grady WM, and Carethers JM; Gastroenterology, 2008]. 
Injurious mechanisms in CIN establishment include alterations in chromosome 
segregation, DNA damage response and telomere dysfunction, affecting critical 
genes (e.g. APC, KRAS, PI3K and TP53) involved in the maintenance of correct cell 
function. The well-known aberrant pathway (Figure 1.3), in this kind of tumors, 
occurs in components of the Wnt signaling. Generally, the chain of events includes 
somatic or inherited mutation in one allele of APC gene, and subsequently LOH of 
the second normal allele. APC mutations triggers the translocation of β-catenin to 
the nucleus, that enhances cell growth and proliferation, laying the fundamental 
step in tumorigenesis. Subsequent mutational activation of KRAS and PI3K leads to a 
constant activation of MAP kinase pathway, forcing a higher cell proliferation rate 
and driving to carcinoma formation, upon mutation or LOH in TP53, the main cell-
cycle checkpoint protein [Pino MS, and Chung DC; Gastroenterology 2010]. 
Figure 1.3. Progression of colorectal tumors with CIN [Grady WM, and Carethers JM; Gastroenterology, 2008]. 
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In CIN progression, TGF-β signaling molecules has been reported to be severely 
affected: noteworthy, loss of heterozygosity at chromosome locus 18q, that harbors 
SMAD4 and SMAD2, and mutations of the kinase domain of TGFBR2 are often found. 
In metastasis processes are involved several genes, among the other PRL3 [Grady 
WM, and Carethers JM; Gastroenterology, 2008]. 
 
The microsatellite instability (MSI) tumors, either sporadic or from patients with 
Lynch syndrome, are characterized by the loss of Mismatch Repair (MMR) function, 
generally as one of the main early step in cancerogenesis, and by histological 
serrated adenoma (non-polyposis). Almost the totality of sporadic tumors loses 
MMR function due to the specific hypermethylation of the promoter of MLH1 gene. 
In contrast, patients with Lynch syndrome present a germline mutation in one of the 
MMR genes (e.g. MLH1, MSH2, MSH6, PMS1 and PMS2). The MMR is involved also 
in repairing insertion/deletion loop in short DNA chains or tandem repeats (two to 
five base-pair repeats), called micro-satellites. Thus, in the context of MMR absence, 
a hypermutable phenotype develops occurring in DNA multiple mutations [Boland 
CR, and Goel A; Gastroenterology, 2010]. The majority of microsatellites affected by 
mutation due to MMR absence are located in noncoding sequences, such as intronic 
regions. Nevertheless, there are several genes that harbor microsatellites in their 
coding sequences (e.g. TGFBR2, ACVR2, BAX, hMSH3, hMSH6), resulting in frameshift 
aberrations. These mutations and subsequent other additional mutations, due to the 
hypermutable phenotype, lead to malignant progression that generally involves Wnt 
signaling alterations and, in Lynch syndrome, CTNNB1 (β-catenin) mutation (Figure 
1.4). Other important mutations involve EGFR signaling pathway: in sporadic tumor 
BRAF mutations are principally found, on the contrary in Lynch syndrome KRAS 
mutations are often found but not BRAF mutation. These features are used to 
differentiate between these 2 groups [Ogino S, et al.; Gut, 2009]. 
Furthermore, TGF-β signaling is altered in a not completely understood way either 
in MSI and non-MSI (MSS, microsatellite stable) tumors. Finally, MSI tumors harbor 
less LOH and are mainly diploid (non-CIN, chromosomal stable), having a better 
prognosis [Umar A, et al.; J. Natl. Cancer Inst., 2004]. On the contrary, MSS tumors 
are generally correlate to CIN-positive and worst prognosis [Ogino S, and Goel A; J. 




Epigenetic instability is another important feature in CRCs. One of the major studied 
epigenetic aberrations in CRCs are the alteration in DNA methylation profile, which 
results paradoxically in local hypermethylation of the CpG islands (CGI) in gene 
promoters and global LINE-1 hypomethylation [Lao VV and Grady WM; Nat. Rev. 
Gastroenterol. Hepatol., 2011]. CpG island hypermethylation is the main effect of 
the so-called CpG island methylator phenotype (CIMP). The principal characteristic 
of CIMP-positive tumors is the abnormal methylation of promoter sequences of 
several tumor suppressor genes, leading to epigenetic silencing of these genes, by 
tightly allied regulation of chromatin structure [Grady WM, and Carethers JM; 
Gastroenterology, 2008]. CIMP tumors in part overlap with, or are comprehensive 
of, sporadic MSI tumors due to hypermethylation of MLH1 gene promoter. A full 
understanding of the progression steps in CIMP-related CRC is not clear (Figure 1.5), 
however seems that hyperplastic Aberrant Crypt Foci (ACF) may be the initial lesion 
in this kind of tumors, in contrast with the dysplastic ACF, typically arisen from an 
altered Wnt signaling. In this initiation phase the hypermethylation of promoter 
genes (e.g. MGMT, EVL, HLTF, SFRP2, SLC5A8, and MINT1) drives the colorectal 
development. Subsequently hypermethylation of MLH1 promoter might lead to the 
development of a serrated adenoma, in accordance with MSI-CRCs progression.  
Figure 1.4. Progression of colorectal tumors with MSI [Grady WM, and Carethers JM; Gastroenterology, 2008]. 
Figure 1.5. Conceptual progression of colorectal tumors with CpG island Methylator Phenotype (CIMP) [Grady WM, 
and Carethers JM; Gastroenterology, 2008]. 
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Hypermethylation of TSP1 and TIMP3 promoters could help to drive the progression 
of CIMP tumors. Beyond the not completely understanding of the progression steps, 
CIMP tumors are particularly interesting due to their tight relationship or 
overlapping with other epigenetic and genetic aberration. An example of the 
combined effect of epigenetics and genetics in CIMP-CRCs development is the strong 
association observed in many CIMP-positive tumors with microsatellite instability 
(MSI) and BRAF mutations [Weisenberger DJ, et al.; Nat. Genet., 2006]. 
 
Genetics and epigenetics alteration are not mutual exclusive events in CRCs, as well 
as in other tumor types. In CRCs both alterations cooperate in its development and 
progression, and notably more aberrant methylation events are found than point 
mutations [Lao VV and Grady WM; Nat. Rev. Gastroenterol. Hepatol., 2011]. This is 
the case of the CRC-derived cell lines RKO (MSI CRC model, CIMP-high, CIN-negative, 
BRAF-V600E, PI3KCA-H1047R), object of this PhD thesis [Ahmed D., et al.; 
Oncogenesis, 2013]. Nevertheless, the effect of the interaction between genetics 
and epigenetics alteration on the patient’s outcome is not completely understood 







1.2. Concepts of Epigenetic 
In the past, the term ‘epigenetic’, originally coined by Waddington in 1942, referred 
to the causal mechanisms by which the environment alters the manifestation of a 
phenotype modifying the subtended genotype outcome. Nowadays, ‘epigenetics’ 
defines the study of inheritable modifications of gene expression that do not involve 
changes in the primary nucleotide sequence and/or in the number of copies of the 
DNA [Bird, A, et al.; Genes & Development, 2002] [Riggs AD, et al.; Regulation in 
Epigenetic Mechanisms of Gene; Cold Spring Harbor, 1996]. Conventionally, all the 
modifications and/or molecular mechanisms involved in the regulation of gene 
expression have considered the epigenome, including either DNA methylation (CpG 
methylation), and chromatin modifications (i.e. hPTMs, post-translational 
modifications of histones, and/or replacement with histone variants). Furthermore, 
recent data indicate that even non-coding RNAs (e.g. miRNAs, lncRNAs, ceRNAs) play 
a pivotal role in the fine-tuning of the epigenetic regulation of gene expression. 
Altogether these epigenetic marks define a peculiar chromatin profile that 
delineates the cell identity. In other term, the heritable instructions that determine 
spatial and temporal changes of gene activation and repression, leads to functional 
distinct cell types characterized by different phenotypes arisen from the same 
genotype [Probst AV, et al.; Nat Rev Mol Cell Biol, 2009].  
 
1.2.1. Chromatin organization and regulation of gene expression 
The epigenetic information relies on a particular structural organization named 
chromatin. Chromatin is the structure in which the DNA is packaged within the cell 
nuclei. The nucleosome is the basic unit of the chromatin and it is composed of an 
octamer of the four core histones (H3, H4, H2A, H2B, each one as dimer) around 
which 147 base pairs of DNA are wrapped [Kouzarides T; Cell, 2007]. There are 14 
contact points between histones and DNA. These multiple interactions make the 
nucleosome one of the most stable protein-DNA complex under physiological 
conditions. For this reason, the histone-DNA complex is evolutionarily conserved and 
adapted to package, organize and regulate the DNA macromolecule (Figure 1.6). In 
fact the nucleosome is not a simple static packaging unit. It possesses dynamic 
properties which are strictly regulated by chemical modification mediated by several 
protein complexes orchestrating the chromatin remodeling and determining 
regulation of the gene expression [Li B, et al.; Cell, 2007]. 
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Transcriptional regulation resides in a complex and fine-tuned protein network that 
results in gene active transcription by the RNA polymerase II. Basically, the 
transcription initiation is controlled by at least three different architectural levels of 
regulation: 
- DNA consensus sequences of transcription factors (common-sequence or 
sequence-specific) [Malik S, and Roeder RG; Trends Biochem. Sci., 2005]; 
- architectural complexity of the core promoter (regulatory elements, multiple 
start sites and alternative promoter) [Smale ST; Biochimica et Biophysica 
Acta; 1997]; 
- control of DNA accessibility by overlying epigenetic processes (DNA 
methylation, and chromatin structural organization like modifications of 
histone and nucleosome positioning) [Berger SL, et al.; Nature, 2007].  
The explosion of epigenetic data in the recent years shows clearly that different 
structures of chromatin impose profound effects on all cell-life processes (i.e. 
transcription, recombination, DNA repair, replication, formation of centromere and 
kinetochore, etc.) [Li B, et al.; Cell; 2007]. Chromatin can be subdivided into two 
major status: heterochromatin, characterized by highly condensed state, late timing 
during replication, and the presence of inactive genes; and euchromatin, which is 
characterized, on the contrary, by open and accessible state and the presence of 
transcriptionally active genes (Figure 1.7). Different distribution of the genome from 
Figure 1.6. Representation of chromatin spatial organization. The image is adapted from online notes of Arianna Macrì 
Blogspot website (Mar 2013). 
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the first to the second chromatin configuration leads to delineate the cell identity 
and the different cellular commitment during development [Reik W; Nature, 2007]. 
 
 
1.2.2. Chromatin modifications and functions 
The dynamics of chromatin structure is regulated by several mechanisms including 
histone post translational modifications (hPTMs), presence of different histone 
variants, chromatin remodeling, and DNA methylation (different CpG methylation 
profile) [Li B, et al.; Cell; 2007]. All these dynamic mechanisms are orchestrated by a 
plethora of chromatin-modifying enzymes that cooperate to chromatin organization 
in a highly-regulated manner [Allis CD, et al.; Cell, 2007]. Chromatin-modifying 
Figure 1.7. Representation of chromatin organization and principal modifications [Aguilar CA, and Craighead HG; 
Nature Biotech, 2013]. 
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enzymes could be classified in ‘writers’, ‘erasers’ and ‘readers’ relying on their 
abilities respectively to add, remove or read different histone and DNA modifications 
[Treviño LS, et al., Prog Biophys. Mol. Biol., 2015]. 
Figure 1.8. Table of chromatin modifications and their functions [Dawson M., and Kouzarides T.; Cell, 2012]. 
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Nowadays, at least 4 different DNA modifications [Wu H, et al.; Genes Dev., 2011] 
and 16 classes of histone modifications [Kouzarides T; Cell, 2007] are known, even if 
the attribution a biological function remain unclear for some of them (Figure 1.8). 
 
DNA Methylation 
DNA methylation is the first epigenetic modification identified and has been 
intensively studied for half a century. In particular, among the DNA modifications, 
the most studied is the addition of methyl groups to the C5 position of cytosines 
(5mC) catalyzed by a family of DNA methyltransferases, named DNMTs. 
DNA methylation occurs essentially in the context of CpG dinucleotides that tend to 
cluster in regions called CpG islands (CGIs). In general, CGIs, which constitute about 
1-2% of the genome, are DNA stretches of more than 200 base pairs in length (from 
0.2 to 3 kb), characterized by an elevated C/G content (at least 50 %) and a high ratio 
of CpG dinucleotide (at least 0.6) [Illingworth RS, and Bird AP; FEBS Lett., 2009]. 
About the half of CpG islands are locate in the proximity of transcription start sites 
(Deaton AM, and Bird AP; Genes & Dev., 2011] and many are associated with 
housekeeping genes and developmental regulators [Meissner A, Cell Stem Cell, 
2011]. About 60% of human genes contains CpG islands in their promoter, which are 
usually unmethylated at all stages of development and in all tissue types (Antequera 
F, and Bird AP; PNAS, 1993), nevertheless some of them (around 6%) become 
methylated in a tissue-specific manner during early development or in differentiated 
tissues [Straussman R, et al. Nat Struct Mol Biol., 2009]. Microarray analyses showed 
that unmethylated regions seem to be established during early embryogenesis, 
mainly as a consequence of transcription factors recognition and localization on the 
specific sequence motifs closely associated with transcription start sites (TSS) 
[Straussman R, et al. Nat Struct Mol Biol., 2009]. In general, DNA methylation is 
mainly observed at centromeres, telomeres, inactive X-chromosomes, repetitive 
sequences and at some tissue-specific CpG island genes, as a stable gene-silencing 
mechanism, and it is associated to other repressive marks of chromatin [Baylin S, and 
Jones P; Nat Rev Cancer, 2011].  
In the DNMTs family, three active methyltransferases have been identified in higher 
eukaryotes: DNMT1, DNMT3A and DNMT3B. DNMT1 is the principal 
methyltransferase of maintenance [Li E, et al. Cell, 1992] that, together with UHRF1, 
recognizes the hemi-methylated DNA, generated during DNA replication [Sharif J, et 
al.; Nature, 2007]. DNMT3A and DNMT3B, act primarily as de novo DNA 
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methyltransferases in establishment of DNA methylation during embryogenesis 
[Okano M, et al.; Cell, 1999]. Interestingly, it has been observed that DNMT3A/3B 
corroborate DNMT1 in DNA methylation maintenance [Jones PA and Liang G; Nature 
Rev. Genet., 2009]. In fact, DNMT3A/3B can anchor nucleosomes containing 
methylated CpGs, in particular nucleosomes containing methylated SINE or LINE 
elements and CpG islands [Jeong S, et al.; Mol Cell Biol., 2009]. The reason of these 
observations could reside in the fact that DNMT3A/3B, conversely to DNMT1, does 
not require the presence of interacting-chromatin-actors (e.g. HP1, MeCp2, EZH2, 
UHRF1, HDAC1, PCNA), or particular histone PTMs profiles, to participate in DNA 
methylation maintenance, after the passage of the replication fork [Jones PA and 
Liang G; Nature Rev. Genet., 2009]. 
Notably, m5C can be actively oxidized to 5-hydroxy-methylcytosine (5hmC) by TET 
family proteins and subsequent deamination and replacement via BER pathway (Guo 
et al., 2011). Although the role of these enzymes in the global DNA de-methylation 
processes are still unclear [von Meyenn F, et al.; Mol. Cell, 2016]. 
 
Histone modifications 
In the last 20 years, a large variety of histone modifications has been found. As 
expected these hPTMs are tightly regulated by enzymes that mediate acetylation 
[Sterner and Berger, 2000], methylation [Zhang and Reinberg, 2001], 
phosphorylation [Nowak and Corces, 2004], ubiquitination [Shilatifard, 2006], 
SUMOylation [Nathan et al., 2003], ADP-ribosylation [Hassa et al., 2006], 
deamination [Cuthbert et al., 2004], proline isomerization [Nelson et al., 2006] and 
crotonylation [Tan et al., 2011]. In general, post-translational histone modifications 
can affect chromatin structure by a direct and an indirect mechanism. In fact they 
can directly alters the condensation of chromatin, by changing the electric charges. 
Figure 1.9. Overview of DNA modifications. The molecules were drawn with MarvinSketch software. 
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For example, the acetylation of lysine residues has the highest potential to de-
condense chromatin since it neutralizes the basic charge of histones and the 
phosphorylation of Serine 10 on H3 is crucial for chromosome condensation and cell-
cycle progression during mitosis and meiosis [Ahn et al., 2005; Fischle et al., 2005; 
Krishnamoorthy et al., 2006]. By indirect mechanisms the composition of histone 
modifications mediates the binding of important protein complexes to the 
chromatin. For example, HP1 (heterochromatin-associated protein 1) binds 
specifically the H3K9me3 [Jacobs and Khorasanizadeh, 2002; Jacobs et al., 2001] and 
is released upon phosphorylation of the adjacent serine 10 during M phase of the 
cell cycle [Fischle et al., 2005]. The most studied histone modifications are lysine and 
arginine methylation, lysine acetylation, serine and threonine phosphorylation and 
lysine ubiquitination. Generally, histone methylations lead to a more condensed 
chromatin, while histone acetylation induces electrostatic repulsions that guide 
chromatin opening [Chen et al., 2014]. Pattern of specific histone modifications 
define heterochromatin and euchromatin domains. In particular, acetylation of 
histone 3 and histone 4 (H3 and H4) or di- or trimethylation (me2 or me3) of H3K4, 
are commonly related to euchromatic regions, while H3K9 and H3K27 methylation, 
are often associated to heterochromatin. In particular, H3K9me3 is associated to 
constitutive heterochromatin, while H3K27me3 is associated to facultative 
heterochromatin [Li B, et al., 2007]. Inside these two “status” of the chromatin, the 
hPTMS are not casually distributed. In fact, its localization is finely regulated and 
generally they localized in specific patterns in promoters, upstream regions, the 5’ 
end of the open reading frame (ORF) 
and the 3’ end of the ORF.  
The information conveyed by 
epigenetic modifications plays a critical 
role in the regulation of all DNA-based 
processes, such as transcription, DNA 
repair, and replication. Consequently, 
abnormal expression patterns or 
genomic alterations in chromatin 
regulators can have profound results 
and can lead to the induction and 
maintenance of various cancers 
[Dawson et al., 2012]. 
Figure 1.10. Schematic representation of the distribution at 
genomic level of the histone modifications in relation to 
transcriptional activity [Li B, et al., 2007]. 
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Crosstalk between Epigenetic Modifications 
The two major epigenetic features, the DNA methylation and the histone 
modifications, are deeply linked. In particular, there are three proteins family that 
specifically recognize methylated CpG sites (mCpG): the methyl-CpG binding domain 
(MBD), the Kaiso and the UHRF protein family (Rottach et al., 2009). The methyl 
binding proteins can recognize specific DNA methylation status and recruit protein 
complexes containing HDACs and histone methyltransferases. [Nan et al., 1998; 
Rottach et al., 2009; Hendrich and Tweedie, 2003; Bird, 2002]. The different histone 
modification patterns, the DNA methylation status and higher ordered structures act 
together mediating their interaction, interference, and/or an inter-functional 
dependency (cross-talk). Due the redundancy and the complexity of this epigenetic 
code and the multiplicity of the protein complexes involved, most of the details of 
these interactions are still under investigation [Kouzarides T; Cell; 2007]. 
However, it is possible to report the following considerations (Figure 1.11): 
- the presence of different types of modifications on the same lysine residues 
undoubtedly results in some form of antagonism between these different 
modifications; 
- the binding of a protein to a specific site can be impaired by an adjacent 
modification, e.g. the phosphorylation of serine H3S10 influences the binding 
of HP1 protein to methylated H3K9 [Fischle et al.; Nature; 2005]; 
- the catalytic activity of an enzyme could be compromised by the modification 
of its recognition site, for example, the isomerization of the proline H3P38 
influences the ability of Set2 to methylate H3K36 [Nelson, C.J., el al.; Cell; 
2006]; 
- an enzyme, in contrast, may be able to more effectively recognize its 
substrate, if there is another specific modification, e.g. the GCN5-
acetyltransferase can recognize H3 more effectively when is present the 
phosphorylation of serine H3S10 [Clements, A., et al.; Mol. Cell; 2003]; 
- cross-talk between the various modifications can occur even when the 
markers are on the histone tails of different histones, but belonging to the 
same nucleosome, e.g. the ubiquitination of lysine in position 123 of histone 
H2B, is critical for the tri-methylation of H3K4; 
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- some histone modifications could interfere with the maintenance of DNA 
methylation, e.g. H3K18ub, ubiquitinated by UHRF1, is essential for the 
maintenance of DNA methylation, enabling methylation activity of DNMT1, 
through interaction with its ubiquitin interacting motif (UIM) [Qin W., et al; 
Cell Research, 2015]. 
 
Epigenetic modifications in cancer 
For a long period, alterations in the genetic code was considered the major cause of 
cancer development. As long as the knowledge about the epigenetic mechanisms 
increased, it became clear that, not only there were a deep rearrangement of the 
epigenome during cancer progression, but that the modulation of epigenetic 
modifications could affect cancer outcome. As for the genetic modifications, the 
epigenetic alterations can be cancer type-specific (Figure 1.12), and they can regard 
many aspect, such as DNA methylation, histone modification, nucleosome 
positioning and micro-RNAs expression [Esteller, 2010]. 
The first epigenetic traits that has been found altered in cancer cells is the DNA 
methylation [Feinberg, 1983; Goelz, 1985]. Cancer cells are characterized by a 
specific epigenome: the CpGs interspersed in the genome, usually highly methylated 
in normal tissues, are heavily hypo-methylated, while the CpGs clustered in the CGIs, 
typically located in gene promoters and usually unmethylated, are hyper-
methylated. Form a functional point of view, DNA hypomethylation correlates with 
chromosome instability, activation of transposable elements and loss of imprinting. 
In fact, the DNA hypomethylation at the DNA satellite loci or in the pericentromeric 
associates with increased chromosomal rearrangements, mitotic recombination, 
and aneuploidy [Eden, 2003; Karpf, 2005]. Repetitive elements, such as L1 (long 
Figure 1.11. Crosstalk between histone modifications [Kouzarides T; Cell; 2007]. 
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interspersed nuclear elements) and Alu (recombinogenic sequence), are silenced in 
somatic cells and become reactivated in human cancer [Schulz, 2006]. In gene 
promoters, high DNA methylation levels affect the gene expression of specific 
pathways, such us, cell cycle, DNA repair, apoptosis and many others [Esteller, 2008]. 
Although the ultimate causes of aberrant DNA methylation remain to be determined, 
several studies showed that alterations in the DNA methylome could be directly 
affected by diet, xenobiotic chemicals, and exogenous stimuli, such as inflammation 
or viral/bacterial infection.  
The changes in the histone modifications are more complex to track, due to the 
complexity of all the possible permutations and combinations (Figure 1.13). In colon 
cancer, it has been shown that the hypermethylation of CGi in the promoters of 
tumor-suppressor genes is associated with a particular combination of histone 
markers: deacetylation of histones H3 and H4, loss of H3K4 tri-methylation, and gain 
of H3K9 methylation and H3K27 tri-methylation [Jones, 2007].  
Nevertheless, as DNA methylation and histone modifications act as mechanisms for 
controlling cellular differentiation, allowing the expression only of tissue-specific and 
Figure 1.12. Table of the major epigenetic aberrations reported in different tumors [Esteller M; N Engl J Med, 2008]. 
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housekeeping genes in somatic differentiated cells, it is possible that the 
inappropriate (re)activation of tissue-specific genes can also plays a role in cancer 








The UHRF1 gene (Ubiquitin-like with PHD and Ring Finger domains 1), is located in 
chromosome region 19p13.3 and encodes the UHRF1 protein, also known as NP95 
or lCBP90. UHRF1 is a modular multi-domain protein able to mediate interactions 
between DNA methylation and histone modifications, by interacting directly with 
DNA and histones [Hideharu Hashimoto, et al.; Epigenetics; 2009]. 
UHRF1 gene, identified in 1998 [Fujimori et al., Mamm Genome, 1998], encodes for 
mainly two isoforms, consisting in 793 (isoform 1) and 806 (isoform 2) amino acid 
residues, with a molecular weight of about 95kDa. At the beginning, it has been 
characterized as a transcription factor that binds to the inverted CCAAT box of the 
topoisomerase 2a promoter and regulates its expression [Hopfner R, et al.; Cancer 
Res., 2000]. Over the last 15 years, several studies demonstrated that UHRF1 has the 
unique property to act as a “reader” for both DNA methylation and specific histone-
modification patterns, to act as a “recruiter” for histone and DNA modifiers [Bronner 
C, et al.; Biochem. Pharmac., 2013] (Figure 1.14a), and more recently, to act as 
“ubiquitin-writer” with an E3-ligase activity [Citterio E, et al.; Mol. Cell. Biology, 2004] 
[Jenkins Y, et al; Mol. Biol. of Cell, 2005] toward H3K23 [Nishiyama A, et al.; Nature, 
2013] and H3K18 [Qin W., et al; Cell Research, 2015]. 
Figure 1.14. Current proposed model of multi-modular interaction of UHRF1 with both DNA and histone modifications. 
(A) UHRF1 recruitment on chromatin through the combined recognition of histones, by TTD-PHD domains of 
H3K9me2/me3 and H3R2un, and recognition of DNA, by SRA domain independently of the methylation status. (B) 
DNA methylation regulatory function of UHRF1, by direct enhancement of its ubiquitin ligase activity, towards N-
terminal lysines of H3 tail by RING domain, upon the interaction of the SRA with HeDNA, reinforcing the stability and 
activity of DNMT1 in chromatin [Harrison JS, et al.; eLife, 2016]. 
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Currently, the E3-ligase activity of UHRF1 it is acquiring greater prominence: in fact, 
it has been shown that UHRF1 ubiquitylates multiple lysines on the H3 tail, nearby 
the UHRF1 histone-binding site, with enhanced activity upon binding to hemi-
methylated DNA stretches (HeDNA) (Figure 1.14b). This result provides a functional 
role for the ubiquitination pattern, mediated by UHRF1, as a nucleation event for 
DNMT1 recruitment to chromatin, in the dynamic context of replicative fork 
[Harrison JS, et al.; eLife, 2016]. 
 
1.3.1 Multi-modular domains and molecular functions of UHRF1 
UHRF1 is a multi-modular domain protein that contains five functional domains, 
characterized by several molecular abilities (Figure 1.15): 
- Ubiquitin-like domain (UBL), present at the N terminal, is still not elucidated 
but is involved, bona fide, in the proteasome degradation pathway, relying 
on the fact that many UBL domain-containing proteins interact with the 26S 
proteasome [Bronner C, et al.; Biochem. Pharmac., 2013]; 
- Tandem Tudor domain (TTD), recognizes specific histone marks, such as 
mono-, di-, and tri-methylation of lysine 9 of histone H3 [Arita K, et al.; 
PNAS, 2012] [Rothbart SB, et al.; Genes & Dev., 2013], in particular the TTD 
is able to bind stably H3K9me3, supported by PHD domain in enhanced 
interaction with H3 tail [Cheng J, et al.; J Biol Chem, 2013], [Xie S, et al.; J 
Biol Chem, 2012], [Rottach A, et al .; Nucleic Acids Res, 2010]. 
- Plant Homeo-Domain (PHD), it is reported that acts as a histone H3 tail-
binding module recognizing the first four residues of H3 N-terminal tail, in 
particular H3R2 unmodified [Hu L, et al.; Cell Res., 2011] [Rajakumara E, et 
al.; Mol. Cell, 2011]; 
- SET and RING Associated (SRA) domain, specifically recognizes and binds 
hemi-methylated CpG dinucleotides, recruiting DNMT1 to hemi-methylated 
DNA to preserve the correct DNA methylation profile during DNA 
replication [Bostick M, et al.; Science, 2007] [Sharif J, et al.; Nature, 2007]; 
in particular, the SRA domain, present only in the UHRF family proteins, has 
the unique ability to flip the methylated cytosine out from the DNA duplex 
allowing the correct methylation of the un-methylated nucleotide by 
DNMT1 [Arita K, et al.; Nature, 2008] [Avvakumov GV, et al.; Nature, 2008]; 
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this is the first example of not-enzymatic sequence-specific DNA-protein 
interaction [Hashimoto H, et al .; Nature, 2008]; 
- RING domain, at the C terminus, is responsible for the E3-ubiquitin-ligase 
activity of UHRF1; it has been shown that UHRF1 is able to ubiquitinate 
several histone substrates in vitro with preference for histone H3, but also 
histone H1 and H2B [Citterio E, et al.; Mol. Cell. Biology, 2004] [Jenkins Y, et 
al; Mol. Biol. of Cell, 2005]; in vivo it has been demonstrated that UHRF1 
mono-ubiquitinates H3K23 [Nishiyama A, et al.; Nature, 2013] and H3K18 
[Qin W., et al; Cell Research, 2015]; furthermore, are reported abilities to 
poly-ubiquitinated other substrates beyond histone, such as DNMT1 [Qin 
W, et al.; J. Cell. Biochem., 2011], recently confirmed together with the 
auto-ubiquitination of UHRF1 itself [Harrison JS, et al.; eLife, 2016], and 
RIF1, part of Double Strand Break (DSBs) repair complexes (ubiquitination 
that mediates Homologous Repair by promotion of BRCA1 pathway) [Zhang 
H. et al.; Nature Communications, 2015]. 
It is clear that UHRF1, through its multi-domain abilities, is one of the main ‘‘cross-
talk protein’’ involved in the maintenance and the regulation of the epigenetic 
information. In fact, by its SRA domain, beyond the well-reported interaction with 
DNMT1 and HeDNA, UHRF1 can also mediate the recruitment of histone deacetylase 
1 (HDAC1) [Unoki M, et al.; Oncogene, 2004], one of the major player in chromatin 
condensation and gene silencing. Further studies have shown that SRA is also able 
to interact with the regulatory domains of the methyl-transferase de novo (DNMT3A 
and DNMT3B) and with the histone methyl-transferase (HMT) G9a [Meilinger D, et 
al.; EMBO reports, 2009]. These informations together with the knowledge about 
the role of the PHD and the TTD domains, leads to propose a model of the 
Figure 1.15. Representation of UHRF1 domains and their functional roles [Bronner C, et al.; Biochem. Pharmac., 2013].  
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propagation of H3K9me3 during DNA replication. UHRF1 binds to methylated H3K9 
already present on the “old” histones in front of the replicative fork, then mediate 
the deposition of methylated H3K9 on the “new” incorporated histones, by its 
recruitment of the HMTs G9a and Suv-39H1 [Xie S, et al.; J. Biol. Chem., 2012]. Since 
UHRF1 is associated to the heterochromatin formation (e.g. in the inactivation of X-
chromosome, pericentromeric regions, and/or subtelomeric) [Karagianni P, et al.; 
Mol. Cell. Biol., 2008] [Dillon N.; Cell Biol.; 2004], it reasonable that UHRF1- 
associated repressive complex (e.g. DNMT1, HDAC1, HMTs) mediates the 
propagation of DNA methylation and H3K9me3 in a mutually reinforced mechanism, 
ensuring the stability of heterochromatic states [Xie S, et al.; J. Biol. Chem., 2012]. 
UHFR1 knockout mice are embryonic lethal. Conversely, in UHRF1-null Embryonic 
Stem cells (ESC), complemented with UHRF1 mutants in SRA or TTD domains, UHRF1 
is able to associate with pericentric heterochromatin, recruits DNMT1 and partially 
rescues DNA methylation defects [Liu X, et al.; Nat. Commun., 2013]. Interestingly, 
these observations were partially confirmed in our recent publication [Qin W., et al; 
Cell Research, 2015], showing the novel intriguing role of the RING domain and 
suggesting a more crucial role of PHD domain in the recruitment of UHRF1 to 
chromatin. In fact, RING domain ubiquitinates H3K18ub, and this histone 
modification is essential for the maintenance of DNA methylation, enabling 
methylation activity of DNMT1, through interaction with its ubiquitin interacting 
motif (UIM) [Qin W., et al; Cell Research, 2015]. Furthermore, recently it has been 
shown that ubiquitination pattern, mediated by UHRF1 on several lysines of H3 (K14, 
K18, K23, K27, K36), is an essential event to recruit strongly DNMT1 to hemi-
methylated DNA stretches (HeDNA), in the dynamic context of replicative fork 
[Harrison JS, et al.; eLife, 2016]. 
Altogether these findings suggest that UHRF1 plays an important role as epigenetic 
regulator, acting in a coordinated fashion for faithful inheritance of the epigenetic 
code.  
 
1.3.2 Role of UHRF1 in cancer pathogenesis 
UHRF1 is involved in a large number of physiological and pathological phenomena, 
from embryogenesis to cell migration and cancer development and progression. In 
normal cells, UHRF1 is expressed exclusively in dividing cells and completely absent 
in terminally differentiated cells. In dividing cells, its expression is tightly regulated: 
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it starts to be expressed in S phase, it reaches the peak in late G1 and it is rapidly 
degraded in M phase upon its phosphorylation [Mousli, 2003]. Its inhibition impairs 
cell cycle progression and induces cell cycle arrest and apoptosis [Bonapace, 2002]. 
Since the pivotal role of UHRF1 in the maintenance of the epigenetic code during cell 
cycle, it is not surprising that UHRF1 is often deregulated in cancer cells. It is 
overexpressed in most of the solid cancer such as breast, lung, bladder, pancreatic, 
colon, prostate and cervical cancer (Bronner 2007; Unoki 2009; Unoki 2004; Unoki 
2010; Jin 2010; Lorenzato 2005; Crnogorac-Jurcevic 2005; Sabatino 2012; Babbio 
2012). In cancer cells, UHRF1 is not cell cycle regulated anymore and it is 
overexpressed throughout the all the phases of the cell cycle.  
Recently it has been shown that the overexpression of UHRF1 in developing 
hepatocytes is sufficient to induce hepatocellular carcinoma, including UHRF1 in the 
list of the oncogenes [Mudbhary et al., 2014]. At molecular level UHRF1 
overexpression directly induces the hypermethylation of specific tumor suppressor 
genes, such as BRCA1, p16INK4A, p73, peroxisome proliferator activated receptor 
gamma (PPAR ) and p21 [Kim 2009; Hopfner 2002; Bronner 2007; Sabatino 2012; 
Alhosin 2012; Daskalos 2011; Guan 2013; Jeanblanc 2005] and a genome-wide 
demethylation by inducing DNMT1 degradation [Mudbhari et al., 2014]. 
In colon cells, we reported that UHRF1 overexpression was sufficient to 
epigenetically silence a large panel of tumor suppressor genes, including PPAR  and 
CDH1 and its overexpression stimulates the migration and the invasion of these 
tumor cells. For cervical and adenocarcinoma of pancreas, UHRF1 has been proposed 
as a biomarker for diagnosis and bad prognosis [Lorenzato et al., 2005; Crnogorac-
Jurcevic 2005]. Recently, it was demonstrated that the disruption between 
DNMT1/PCNA/UHRF1 acts as an oncogenic event and one of its signatures (i.e., the 
low level of methyl-transferase activity) is a molecular biomarker associated with 
prognosis in patients with glioblastoma [Hervouet 2010]. In non-muscle-invasive 
bladder cancer, UHRF1 overexpression is an independent prognostic factor for tumor 
recurrence [Yang 2012]. 
These observations are not surprising since UHRF1 is a major effector in the reading 
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Colorectal cancer (CRC) is the third most common cancer, and one of the major 
leading cause of cancer death (fourth in men and third in women) [Ferlay J., et al.; 
Int. J Cancer., 2015]. CRCs, as well as other tumor types, are a complex multifactorial 
disease. In the last decades, an incredible amount of data demonstrates the 
importance of epigenetic processes at all stages of cancer development, leading to 
the realization that genetics and epigenetics cooperate to alter the biological 
processes that are fundamental to the genesis and progression of cancer [Dawson 
MA, et al.; Cell, 2012]. 
In Colon cancer, genetic and epigenetic alterations are tightly connected and 
together they cooperate to determine the tumor aggressiveness and patient’s 
outcome. In fact, CRCs can be classified based on some epigenetic and molecular 
features, like microsatellite stability (MSS) or instability (MSI) and hypermethylation 
of CpG islands (CIMP), however genetic mutation (e.g. BRAF and KRAS) can deeply 
influence the prognosis. Their interaction is complex: for example, MSI-high tumors 
carry a good prognosis whereas the presence of a BRAF mutation confers a poor 
outcome. However, CIMP-high, that is tightly associated with MSI tumors and BRAF 
mutation, appears to eliminate the adverse effect of BRAF mutation, carrying better 
prognostic and predictive qualities [Ogino S., et al.; Gut. 2009]. Nevertheless, the 
effect of the interaction between genetic mutations and epigenetic changes on the 
patient’s outcome is not completely understood [Wu C and Bekaii-Saab T; 
Chemotherapy Research and Practice, 2012]. 
UHRF1 is a key master epigenetic regulator that couples the preservation of histone-
modifications through the cell cycle with maintenance of DNA methylation. UHRF1 
is over-expressed in numerous tumor types. In colon cancer cells, it recruits Suv39H1 
and DNMTs on specific gene promoters, such as PPAR , E-cadherin and RARβ, 
mediating their epigenetic silencing [Sabatino L, Fucci A, et al.; Oncogene, 2012]. We 
recently published that UHRF1 ubiquitinates K18 of histone H3 and this modification 
is essential for the maintenance of DNA methylation, enabling methylation activity 
of DNMT1, through interaction with its ubiquitin interacting motif (UIM) [Qin W., et 
al; Cell Research, 2015]. 
Relying on all these observations, this PhD project arises from the idea that UHRF1 
could play a crucial role in the modulation of DNA methylation changes occurring 
during CRC progression, cooperating with other molecular factors and influencing 
tumor’s outcome. The overall aim of this PhD thesis was to evaluate the role of 
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UHRF1 in the regulation of DNA methylation both at genome-wide and at locus 
specific level in colon cancer, and investigate the intriguing activity of UHRF1 as 
histone post-translational modifications (hPTMs) “writer”. 
In the attempt to better understand the role of UHRF1 in colon cancer, we took 
under exam a large cohort of CRC samples (MSI n =47, and MSS n =88) and controls 
(adenoma n =25). This analysis helped us to define the importance of UHRF1 in the 
CRC outcome. Therefore, to deepen the molecular mechanism that underlies the 
clinical observations, we decided to analyze two cell lines: RKO cells, a cell line 
derived from MSI CRC, and HT29, derived from MSS CRC. Afterwards, we chose RKO 
cells (UHRF1-high, MSI CRC model, CIMP-high) in order to modulate the level of 
UHRF1, and evaluate the effect on DNA methylation patterns, genes expression and 
histone PTMs profile (in particular the changes of ubiquitination pattern in the 
histone tails). 
 
According to this approach, the present work was focused to enlighten the following 
aspects: 
- Evaluation of UHRF1 and DNA methylation levels in human specimens; 
- Analysis of UHRF1 and DNA methylation levels in colorectal-cancer-derived 
cell lines (RKO & HT29); 
- Evaluation of the effect of UHRF1 knock down on DNA methylation, gene 
expression and histone modifications in RKO cells; 
- Genome wide analysis of the effect of UHRF1 silencing on the methylome 
and the transcriptome; 
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3.1. Patients and samples 
Patients samples derived form a collection of 135 Formalin-Fixed Paraffin-
Embedded (FFPE) CRC samples, including 83 tumors previously examined for 
microsatellite instability at high frequency (MSI) and for gene-specific methylation 
(Furlan D, 2013). The newly added cases comprise 28 MSI and 22 microsatellite 
stable (MSS) CRCs which were collected from Ospedale di Circolo, Varese and from 
Fatebenefratelli Hospital in Benevento (Italy). Twenty-five samples of histologically 
normal colorectal mucosa were also analyzed in this study. Of these, 12 samples 
derived from patients without evidence of neoplastic malignancies and 13 from 
morphologically normal mucosa adjacent to a CRC. All tumors were histologically 
reviewed according to the WHO classification of tumors of the digestive system 
(Hamilton SR, 2010) and the TNM staging system (Edge SB, 2010) by a 
histopathology physician (dott.sa Chiaravalli in Ospedale di Circolo, varese). 
Outcome data were collected by consulting clinical records and/or the Tumor 
Registry of the Lombardy region (Italy) and were available for all patients. Ninety-six 
patients (71%) died of disease while fifty-eight patients (29%) were alive (median 
follow-up time of 24 months and 69.2 months, respectively). The study was 
approved by the Ethics Committee of the Ospedale di Circolo, Varese, Italy. 
 
3.2. Immunohistochemical analysis 
FFPE 3-μm sections were dewaxed, rehydrated, and dipped in 3% hydrogen peroxide 
in water solution for 10 min. After antigen retrieval by pressure cooking in 1 mmol 
EDTA buffer (pH 8) for 30 seconds, sections were incubated overnight with 1:4000 
anti UHRF1 monoclonal antibody. A peroxidase polymeric amplification system 
(HRP-Ultravision LP, LabVision, Suffolk, UK) was subsequently applied according to 
the manufacturer's specification and the reaction product was visualized with 3-3ʹ 
diaminobenzidine (DAB). After washing in water, sections were counterstained with 
hematoxylin, dehydrated, and mounted permanently. All the steps were performed 
manually. 
 
The immunostaining was considered positive only when nuclear staining was 
present. Positivity to UHRF1 staining was determined by assessing the percentage 
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of positive cells. Percentage of positive cells was calculated both for the CRC samples 
and the control tissues. 
 
3.3. Cell Cultures 
Human colon carcinoma cell lines (RKO and HT29), human prostate carcinoma cell 
line (PC3), 293T and HeLa cells were purchased from the American Type Culture 
Collection (Manassas, VA, USA) and cultured as monolayer at 37°C and 5% CO2. 
293T and PC3 cells were grown in RPMI 1640 medium (Euroclone), supplemented 
with 10% of heat-inactivated foetal bovine serum (Euroclone), 1% L-glutamine 
(Sigma-Aldrich) and 1% Penicillin/Streptomycin (Sigma-Aldrich). 
RKO, HT29 and HeLa cells were grown in DMEM medium (Euroclone), supplemented 
with 10% of heat-inactivated foetal bovine serum (Euroclone), 1% L-glutamine 
(Sigma-Aldrich) and 1% Penicillin/Streptomycin (Sigma-Aldrich). 
3.4. siRNAs and transfection 
siRNA against UHRF1 was purchased form Invitrogen. To the setup, two different 
siRNAs were used and, both of them under the same experimental conditions, gave 
similar results.  
Transfections have been performed by using either Interferin (Polyplus) or RNAiMax 
(Life Technologies). Briefly 50000 cells were plated in a 6 well-plate. 24 hours after 
plating, the transfection has been performed as suggested in the manufacturers’ 
instructions (two different protocols for the two reagents) by using 10nM final 
concentration of the siRNA.  For the setup, the efficiency of the silencing has been 
monitored at 24, 48 and 72 hours after transfection.  
By using the RNAiMax reagents and 10nM of siRNA, the 60% of the UHRF1 protein 
was depleted after 48 hours and at 72 hours, more that 95% of UHRF1 protein was 
silenced. These results were reproducible among the different biological replicates. 
Therefore, we decided to follow this protocol (10nM of siRNA for 72 hours) for all 
the experiments.   
Materials and Methods 
32 
3.5. RNA extraction and Retrotranscription 
Sub confluent (for the basal characterization) or 3 days transfected cells were 
washed by using 1X PBS (Sigma Aldrich). RNA was extracted using Trizol reagent (Life 
Technologies) following the manufacturer’s instructions. RNA was quantified by 
spectrophotometer or Q-bit (Life Technologies). 
0.5 to 5 μg of RNA was treated with 4U of TURBO DNAseI (Ambion) for 30 minutes 
at 37°C and then RNA was extracted by standard phenol:chloroform procedure.  
Extracted RNA was used either for RNA-seq analysis or retrotranscribed for PCR 
experiments. or 0.5 to 1 μg of RNA was retrotranscribed using SSIII Superscript (Life 
technologies) with oligodT. cDNA was diluted at 5ng/ l and used for the PCR 
analysis.  
3.6. DNA extraction  
DNA from normal and tumor FFPE samples were obtained from manually 
microdissected tissues using a QIAamp® DNA FFPE Tissue kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol.  
DNA from cells was extracted by using PureLink® Genomic DNA columns 
(Invitrogen).  
DNA was quantified by Qbit and used for MS-MLPA, pyrosequencing or RRB-
sequncing. 
3.7. Methylation-Specific Multiple Ligation-dependent Probe 
Amplification (MS-MLPA) analysis 
Promoter methylation of a total of 34 genes using (MS-MLPA) with SALSA MS-MLPA 
ME001 Tumor suppressor-1 Kit and SALSA MS-MLPA ME002 Tumor suppressor-2 Kit 
(MRC-Holland, Amsterdam, The Netherlands) were already available for 83 CRCs 
(Furlan D, 2013). We extended this analysis to the newly added CRCs as well as to 
CRC cell lines and the 25 samples of the normal colorectal mucosa. Transfected RKO 
and HT29 cells were further tested for the presence of promoter methylation of the 
Mismatch Repair genes by using SALSA MS-MLPA KIT ME011 Mismatch Repair genes 
(MRC-Holland, Amsterdam, The Netherlands). 
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3.8. Bisulphite pyrosequencing analysis 
Bisulphite conversion was performed by using EpiTect Plus DNA Bisulfite Kit (Qiagen, 
Hilden, Germany). Converted DNA was analyzed by pyrosequencing in collaboration 
with dr. Daniela Furlan at the Ospedale di Circolo di Varese.  
3.9. Polymerase Chain Reaction (PCR) 
Primers were designed by using the open-access tool Primer 3 software 
(http://fordo.wi.mit.edu/website) choosing amplicons of approximately 75-135bp 
(see primers table). The selected sequences were validated in silico by using 
primerBLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) to confirm the 
specificity of the target. The melting temperature was experimentally determined 
for each primer pairs. 
 
3.9.1. Semi-quantitative PCR 
The semi-quantitative PCR was performed using the HotStart GoTaq polymerase 
(Promega Inc.) following the manufacturer’s instructions. The amplicons were 
separated on 1.5% agarose gel and visualized by ethidium bromide staining (Sigma 
Aldrich) at luminometer. 
 
3.9.2. Quantitative real-time PCR 
Quantitative real-time PCR was performed in iCycler iQ (BioRad) by using 2X 
iQ™SYBR Green Supermix (BioRad). Data were analysed by averaging triplicates Ct. 
Levels of RNA expression were determined by Gene Expression Analysis for iCycler 
iQ Real-Time PCR Detection System v1.10 (Bio-Rad) according to the 2-ΔΔCq 
method. Levels of RNA expression of selected genes were normalized to the internal 
control reference gene (GAPDH). 
Post-PCR melting curves were used to assess the quality of primer pairs. 
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3.10. Western Blot 
Sub confluent (for the basal characterization) or 3 days transfected cells were 
washed using 1X PBS (Sigma Aldrich), and directly lysed by using 2X Leammli (Life 
Technology). Lysates were sonicated and boiled 5 minutes at 95°C; proteins were 
separated on a gradient gel (4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 
BioRad) under reducing conditions and transferred onto polyvinylidene fluoride 
membranes (Amersham, Biosciences, Otelfingen, CH, USA), which were then 
incubated with the specific antibodies. 
Horseradish-peroxidase-conjugated secondary antibodies against rabbit or mouse 
immunoglobulin (Cell Signaling Technology; 1:5000) were then used and reactions 
were visualized with the enhanced chemiluminescence kit (ECL) from GE Healthcare. 
Lysates were normalized using GAPDH protein as reference. 
3.11. Chromatin Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation assay was performed according to a previously 
published method (Raha 2005) with some modifications. Briefly, cells were treated 
with 1% formaldehyde and collected in 1X PBS. Cell pellets were re-suspended in 
lysis buffer (5mM PIPES pH8, 85mMKCl, 0,5% NP40, 1X Proteinase inhibitors) and 
sonicated for 10 seconds 18 times on ice (BRANSON S250 digital sonicator, Branson, 
Danbury, CT, USA). Sonicated chromatin was pre-cleared for 1 hour at 4°C using 60μl 
of pre-washed sepharose beads (KPL). Pre-cleared chromatin was quantified using 
Qubit® dsDNA BR Assay Kit (Life Tecnologies). 10μg of chromatin was incubated 
overnight at 4°C in dilution buffer (1% SDS, 10mM EDTA pH8, 50mM Tris-HCl pH8, 
1X proteinase inhibitors) with 10μg of specific antibodies. Five percent of the total 
non-immunoprecipitated lysate was used for input control. Antibody coupled-
chromatin was incubated using 60μl pf pre-washed protein G sepharose beads (KPL) 
for 2 hours at 4°C. The beads were extensively washed and the DNA was extracted 
by the phenol:chloroform:isoamyl alcohol, ethanol precipitated and resuspended in 
water. Chromatin immunoprecipitation products were amplified using GoTaq Hot-
Start Polymerase (Promega Inc.) and specific primers. 
To better compare the ChIP results, densitometric analysis was performed using 
ImageJ program. First, the obtained values were normalized on input signals as 
follow: IP) / Densitometric value (INPUT)) X 5 (% of the INPUT) 
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The resulting value represents the % of the recovery of the antibody. This value 
indicates the amount of the specific DNA sequence recovered by a specific antibody. 
3.12. RRBS and data analysis  
Reduced representation bisulfite sequencing (RRBS) was obtained using 4 µg of high-
quality gDNA that was restriction digested using the methyl insensitive restriction 
enzyme Mspl, which cuts the DNA at CCGG sites. The fragments were blunt-ended, 
3’-end A-tailed and ligated to indexed adaptors using the TruSeq DNA PCR-free 
protocol (TruSeq Stranded DNA PCR-free Sample Preparation Kit, Illumina, San 
Diego, CA, USA); the ligation products purified (400 ng) were bisulfite-treated with 
the EZ DNA Methylation kit (Zymo Research) and PCR-amplified to enrich fragments 
using Taq PFU CX (Agilent). Libraries were sequenced (paired-end, 2x100 cycles) at 
a concentration of 8pmol/L per lane on HiSeq2500 platform (Illumina) with >50 
million sequence reads/sample. The raw sequence files generated (.fastq files) 
underwent quality control analysis using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The adapter was 
trimmed using TrimGalore (Version 0.4.0) 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The sequence 
data obtained were analyzed using Bismark (version 0.16.1) and methylation 
profiling were analyzed using methylKit (version 0.9.5). Annotation of CpG was 
performed with Homer (version 4.6). 
3.13. RNA sequencing and data analysis  
Indexed libraries were prepared from 1 g/ea purified RNA by using TruSeq 
Stranded Total RNA Sample Prep Kit (Illumina) according to the manufacturer’s 
instructions. Libraries were sequenced (paired-end, 2x100 cycles) at a concentration 
of 8pmol/L per lane on HiSeq2500 platform (Illumina) with >70 million sequence 
reads/sample. The raw sequence files generated (.fastq files) underwent quality 
control analysis using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and the quality 
checked reads were then aligned to the human genome (hg19 assembly) using 
TopHat2 (version 2.0.13), with standard parameters. A given mRNA was considered 
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expressed when detected by ≥10 reads. Differentially expressed mRNAs were 
identified using DESeq (version 1.6.3). Firstly, gene annotation was obtained for all 
known genes in the human genome, as provided by Ensemble (GRCh37) 
(https://support.illumina.com/sequencing/sequencing_software/igenome.ilmn). 
Using the reads mapped to the genome, we calculated the number of reads mapping 
to each transcript with HTSeq-count (version 0.6.0). These raw read counts were 
then used as input to DESeq for calculation of normalized signal for each transcript 
in the samples, and differential expression was reported as Fold Change along with 
associated adjusted p-values (computed according to Benjamini-Hochberg). Analysis 
of LINE-1 were performed using RepEnrich (version 1.2).   
3.14. Histone acid extraction 
Cells were washed by using PBS and directly scraped in PBS. Cell pellets were 
resuspend in 1 ml of Hypotonic buffer (10mM Tris_HCl pH8, 1mM KCl, 1.5mM MgCl2, 
1mM DTT an proteinase inhibitor Cocktail) and transfer to 1.5 ml eppendorf (more 
or less 107 cells for 1 ml). Incubate for 30 min on rotator at 4°C. 
Nuclei were pelleted by centrifuging at 10000 g for 10 min at 4°C.  The cell nucei 
were resuspended in 1ml of Low salt buffer (0.6M NaCl, 10mM Tris-HCl pH 8, 20mM 
EDTA and proteinase Inhibitor Cocktails) and incubate for 30 min on rotator at 4°C. 
Chromatin was pelleted by centrifuging at 10000 g for 10 min, resuspended in 500 
l of H2SO4 0.2M. (0.2M sulforic acid) and incubated at least 30 min on ice. The 
chromatin was manually disgregated and the supernatant containing the histones 
was collected. Histones were precipitated by adding TCA (final concentration 33%), 
incubated, incubated on ice for 30 min and centrifuged at 16000 g for 5 min at 4°C. 
Final pellet containing histones was resuspended in 50 l of water. Histones were 
used for either WB or SILAC analysis.  
3.15. SILAC experiments 
Control and UHRF1 silenced cells were grown in SILAC media (lysine- and arginine-
free DMEM/Ham’s F12 (1:1), 10% dialyzed fetal bovine serum (FBS, Invitrogen)), 
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supplemented with 1mM non-essential amino acids (Gibco), 100 U/ml of penicillin 
and streptomycin (Lonza), 1mM Na-pyruvate (Gibco), 2mM Glutamine (Lonza) and 
50 mM β-mercaptoethanol (Gibco)). “Heavy” and “Light” media were obtained by 
adding 0.146 g/L 13C6, 15N2L-Lysine and 0.84 g/L 13C615N4L-Arginine (Sigma) or 
the corresponding non-labeled amino acids, respectively to the SILAC media. 
Growth in SILAC media was carried out for eight duplications, to ensure complete 
protein labeling. For the experiments transfected cells were labeled with heavy 
medium, and control cells with light medium.  
“In solution” digestion using Arg-C 
Equal numbers (12×106) of heavy and light cells were mixed and 10 g of histones 
were incubated overnight at 37 C with endoproteinase Arg-C. After incubation the 
reaction was stopped by adding 50% volume of TFA. Product peptides were 
separated according to their isoelectric point by isoelectrofocusing electrophoresis 
using the Agilent 3,100 OFFGEL Fractionation Kit (Agilent Technologies). Samples 
were prepared and separated according to the manufacturer’s protocol. After 
separation, peptides mixtures were reconstituted with 1% TFA and desalted on C18 
STAGE tips. 
“In-gel” digestion  
Protein samples were separated on a 8–12% gradient mini gel (Invitrogen). After 
Coomassie staining (Colloidal Blue Staining Kit, Invitrogen), each line was cut 
according to the specific bands and trypsin digested according to a previously 
described protocol (J. Rappsilber, et al., Nat. Protoc. 2007). Briefly, after distaining 
with 50% acetonitrile (ACN)/25 mM ammonium bicarbonate (NH4HCO3) solution, 
and dehydration by 100% ACN, gel pieces were incubated with 10mM dithiothreitol 
in 50mM NH4HCO3 for 60 min at 56°C for cysteine reduction and then alkylated with 
55mM iodoacetamide in 50mM NH4HCO3 for 45 min at room temperature, in dark. 
After several rounds of washings with 50mM NH4HCO3 and dehydration with 100% 
ACN, proteins were digested with trypsin overnight, at 37 °C. The reaction was 
stopped by acidification with 2μl of 50% trifluoroacetic acid (TFA). Peptides were 
eluted with 30% ACN/3% TFA and 100% ACN. After speed-vacuum centrifugation, 
peptides were solubilized in 100μl of 0.1% formic acid (FA), desalted and 
concentrated using reverse phase C18 Stage Tips. Peptides were eluted with 80% 
ACN, lyophilized and re-suspended in 7μl of 0.1% formic acid for LC–MS/MS analysis. 
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3.16. Statistical analysis  
Association analyses were performed using the Fisher exact test, ANOVA analysis, 
and the independent sample t-test.  To define an appropriate threshold for UHRF1 
immunohistochemical positivity a model based cluster algorithm (Raftery 2002) was 
used. Patient survival was evaluated using the Kaplan-Meier method and statistically 
tested with the log-rank test. Multivariate analysis was performed with the Cox 
Proportional hazard model using the backward method. A p-value <0.05 was 
considered statistically significant. These analyses were performed using MedCalc 
Statistical (version 11.0.1.0) and GraphPad Prism V5.0 software.  
3.17. Primers and oligonucleotides 
Gene 
name 
FOR REV Methods 
UHRF1 CTGGTACGACGCGGAGAT CGACAGTCGTTCAGAGAATCA PCR 
MLH1 ACTCCTGGAAGTGGACTGTG GATCAGGCAGGTTAGCAAGC PCR 
CDH1 ATGAGTGTCCCCCGGTATCTTC ACGAGCAGAGAATCATAAGGCG PCR 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG PCR 
    
MLH1-5 CTTGCTTCTTTTGGGCGTCAT GGCTTGTGTGCCTCTGCTGA ChIP 
MLH1-6 CCCAGCAACCCACAGAGTTGAG CGGAAGTGCCTTCAGCCAATC ChIP 
CDH1-1 GAACTCAGCCAAGTGTAAAAGC AGACGCGGTGACCCTCTA ChIP 
CDH1-2 TAGAGGGTCACCGCGTCTAT GACTTCCGCAAGCTCACAG ChIP 
LINE-1 GGCCAGTGTGTGTGCGCACCG CCAGGTGTGGGATATAGTCTCGTGG ChIP 
 
Genomic schemes of ChIP primers. 
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3.18. Antibodies 
Protein name Supplier Dilution Application 
UHRF1 IGBMC, monoclonal 1:4000; WB, ChIP 
UHRF1 Bonapace’ s Lab 1:4000 IHC 
CDH1 BD Biosciences, monoclonal 1:3000 WB 
MLH1 BD Biosciences, monoclonal 1:1000 WB 
IgG Santa Cruz  ChIP 
H3K4me3 Active Motif, polyclonal  ChIP 
H3K9me3 Active Motif, polyclonal  ChIP 
H3K27me3 Active Motif, polyclonal  ChIP 
DNMT1 Active Motif, monoclonal 1:250 WB, ChIP 
DNMT3a Active Motif, monoclonal 1:1000 WB, ChIP 
DNMT3b Active Motif, monoclonal 1:1000 WB, ChIP 
Ub total Cell signaling, monoclonal 1:1000 WB 
H3 Abcam, polyclonal 1:3000 WB 
H2BK120ub Active Motif, monoclonal 1:1000 WB 
GAPDH Millipore, monoclonal 1:4000 WB 













4.1. Evaluation of UHRF1 and DNA methylation levels in human 
specimens 
In the attempt to better understand the role of UHRF1 in colon cancer and its 
possible involvement in the regulation of DNA methylation both at genome-wide and 
at locus-specific level, we performed IHC analysis of UHRF1 protein in a cohort of 
colorectal mucosa specimens, in collaboration with Dr. Daniela Furlan (Anatomic 
Pathology Unit, University of Insubria, Varese, Italy), Dr. Anna Maria Chiaravalli 
(Anatomic Pathology Unit, University of Insubria, Varese, Italy) and Prof. Vittorio 
Colantuoni (Dept. BGES, University of Sannio, Benevento, Italy). 
 
4.1.1. UHRF1-high correlates with MSI colorectal cancer and better prognosis 
IHC analysis of UHRF1 was performed in a cohort of colorectal mucosa samples, 
composed by 25 normal mucosae (divided in 13 adenomas near to CRCs, and 12 
normal mucosae from healthy patients) and 135 colorectal cancer samples (divided 
in 47 MSI CRCs, and 88 MSS CRC).  
Figure 4.1. Immunohistochemical analysis of UHRF1 in normal colonic mucosa. a) Representative diagram of a normal 
colonic mucosa (Sabatino et al, 2012). b) IHC analysis of UHRF1: UHRF1 nuclear staining depicts the lower third of the 
crypt, marking the cells with the highest proliferative index, as shown in the representative diagram on the left. UHRF1 
is detected with ABC-peroxidase, DAB-hematoxylin (100x). 
A: Lamina propria; B: intestinal crypt; C: Detail of the lower third of the crypt. 
Red arrow: cells positive to UHRF1 staining; Black arrow: cells negative to UHRF1 staining. 
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UHRF1 showed a nuclear positive staining in the lower third of the crypt, in the 
normal colonic mucosa (Figure 4.1b) where are located the cells in active 
proliferation (Figure 4.1b, red arrows). The enterocytes, terminally differentiated 
cells, in the middle-upper part of the crypt, showed a UHRF1 negative staining, in 
accordance with our previous reports [Sabatino et al.; Oncogene, 2012] [Bonapace 
et al.; J. Cell. Biol., 2002]. 
The normal mucosae, adjacent respectively to MSS (Figure 4.2a) and MSI (Figure 
4.2b) tumors, showed a staining similar to what we observed in the normal mucosa, 
as shown in Figure 4.1b. 
On the contrary, the tissue architecture of the tumor samples is completely 
subverted (Figure 4.3). Colon cancer cells, in adenocarcinomas, can extend from 
mucosa to muscle layer and beyond, and infiltrate in solid individual groups or 
aggregate in glandular and tubulo-papillary structures. 
IHC analysis showed that the number of UHRF1 positive cells are significantly 
increased in CRC samples compared to the normal mucosa (Figure 4.3). Surprisingly, 
among the CRC groups, UHRF1 is significantly higher in MSI CRC samples, which have 
a better prognosis, compared to MSS CRC (Figure 4.4). 
  
Figure 4.2. Immunohistochemical assay of UHRF1 in normal colonic mucosa adjacent to CRCs: a) Close to MSS-CRC; b) 
Close to MSI-CRC. In both cases, UHRF1 nuclear staining depicts the lower third of the crypt, similar to control shown 
in figure 4.1b. UHRF1 is detected with ABC-peroxidase, DAB-hematoxylin (100x). 
A: Lamina propria; B: intestinal crypt; C: Detail of the lower third of the crypt. 




Figure 4.3. Immunohistochemical analysis of UHRF1 in CRC tissues: a) Two representative slices of human MSS-CRC; 
b) Two representative slices of human MSI-CRC. UHRF1 positive cells were counted in each field, for a total of 5 fields 
per slide. UHRF1 is detected with ABC-peroxidase, DAB-hematoxylin (100x). 
Red arrow: cells positive to UHRF1 staining; Black arrow: cells negative to UHRF1 staining. 
Figure 4.4. Plot of the average percentage of UHRF1 positive cells. UHRF1 positive cells were calculated with a model 
based cluster algorithm (Raftery 2002). The result was expressed in percentage of positive cells normalized on the 
total number of cells. The statistical significance was evaluated by the t-test. 
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In order to assess the possible correlation between UHRF1 positivity and patient’s 
outcome, all CRCs were divided into two groups using a cut-off value of 50% of 
UHRF1 positive cells, that was calculated by using a model based cluster algorithm 
[Fraley C. and Raftery AE; Journal of the American Statistical Association, 2002]. We 
defined as UHRF1 low (UHRF1-L) the samples with less than 50% of positive cells per 
field and UHRF1 high (UHRF1-H) the samples with more or equal 50%. This threshold 
value clearly separated two subsets of 43 and 92 CRCs, exhibiting low- (UHRF1-L) or 
high- (UHRF1-H) positivity of the protein, respectively (Figure 4.5a). The UHRF1-H 
group significantly correlated with the better prognosis, in terms of overall survival.  
We also observed that UHRF1-H CRCs were strongly associated with MSI (p=0.0019) 
and with BRAF mutation (p=0.013) (data not shown). Surprisingly, univariate survival 
analysis (Figure 4.5b, Kaplan-Meier) showed that UHRF1-H was correlated with 
better prognosis compared with UHRF1-L (p=0.02). 
 
4.1.2. Aberrant DNA methylation profiles in MSI and MSS CRCs correlates with UHRF1 
positivity 
UHRF1 positivity correlated with DNA methylation profiles in normal colorectal 
tissues as well as in MSI and MSS CRCs (Figure 4.6). We analyzed global DNA 
methylation, by the pyrosequencing analysis of the repetitive sequence LINE-1, 
considered as a surrogated of global DNA methylation. Gene-specific methylation 
was assessed by performing MS-MLPA assay on 34 selected Tumor Suppressor Genes 
(TSGs) promoters. MS-MLPA is a well-established assay used for the clinical 
Figure 4.5. a) Stratification of the series of 135 CRCs based on the levels of UHRF1 immunohistochemical expression. 
The threshold value (<50% positive cells: UHRF1-L; ≥50% of positive cells: UHRF1-H) was calculated by applying the 
algorithm of Model Based Clustering (ref). b) Univariate survival analysis according to UHRF1 immunohistochemical 
expression in CRCs. 
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characterization of the tumors. We observed an overall global hypomethylation and 
a gene specific hypermethylation in the CRC groups (Figure 4.6, box plot, middle and 
right part) compared to normal mucosae (Figure 4.6, box plot, left part). This data 
supported the actual paradigm for solid tumors development in which genome-wide 
hypomethylation and gene-specific hypermethylation are constantly associated in all 
solid tumors including the CRCs [Esteller M; N. Engl. J. Med., 2008] [Ehrlich M; 
Epigenomics, 2009]. Nevertheless, considering the CRCs only (Figure 4.6, MSI vs. 
MSS-CRCs), high levels of UHRF1 correlated to higher degree of DNA methylation 
both at global and at specific sites. This detailed comparison between DNA 
methylation levels in MSI and MSS CRCs enlightened a new intriguing finding 
regarding UHRF1 overexpression in cancer. In fact, in several cancer types, UHRF1 
deregulation and overexpression were associated to cancer progression and worse 
prognosis [Unoki M., et al.; Br J Cancer., 2010] [Babbio F, et al.; Oncogene, 2012] 
[Mudbhary R, et al.; Cancer Cell, 2014]. However, comparing only the MSI and MSS 
CRC groups, that showed as expected an overall UHRF1 overexpression compared to 
normal mucosae, UHRF1-high correlated with MSI model and with a better 
prognosis.   
Figure 4.6. Correlation Box Plot: UHRF1 IHC analysis (pink), LINE-1 methylation measured by pyrosequencing, 
considered as surrogated of global methylation (purple) and gene specific methylation levels measured by MS-MLPA 
analysis (green). The table (top right) represented the p-value of the different correlation reported. The percentages 
on Y axis represented respectively IHC percentage of positive cells for UHRF1 staining and percentages of DNA 
methylation at global level (LINE-1 pyrosequencing) and gene promoters (MS-MLPA). 
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The experiments performed in this part of the thesis clearly demonstrated that the 
number of UHRF1 positive cells is significantly increased in CRCs compared to normal 
mucosa, in accordance with our previous publication [Sabatino L, Fucci A, et al.; 
Oncogene, 2012]. Here, we performed a more detailed analysis and we defined a 
strong correlation between UHRF1 positivity and MSI colorectal cancer. In fact, 
surprisingly, among the CRC groups, UHRF1 was significantly higher in MSI CRC 
samples, which have a better prognosis, compared to MSS CRCs. Furthermore, 
UHRF1 positivity correlated with an overall DNA hypermethylation among the CRC 
samples, both at genome-wide and at gene specific level. This could result in a sort 
of protective condition for the genome integrity, that, despite the tumor suppressor 
genes hyper-methylation, leads to a better prognosis [Estécio MRH, et al.; PLoS ONE, 
2007] [Matsuzaki K, et al.; Clin. Cancer Res., 2005] [Holm TM, et al.; Cancer Cell, 
2005]. 
 
This new intriguing data, observed in human specimens, supported us to deepen the 
molecular mechanism that underlies this clinical phenomenon. The project has been 
developed further analyzing UHRF1 and DNA methylation levels in two cell lines: RKO 




4.2. Analysis of UHRF1 and DNA methylation levels in colorectal-cancer-
derived cell lines (RKO & HT29) 
To deepen the molecular mechanism that underlies the clinical phenomenon 
previously observed, we broadened the analysis to two cell lines: RKO cells, a cell line 
derived from MSI CRC, and HT29, derived from MSS CRC. 
 
4.2.1. UHRF1 protein levels in RKO and HT29 are consistent with MSI and MSS-CRCs 
As first step, we needed to evaluate and analyze the molecular features of the two 
CRCs cell lines. In WB analysis (Figure 4.7), we observed very different levels of 
UHRF1 protein in the two cell lines. In fact, RKO 
(MSI-CRC cell lines) showed higher levels of UHRF1 
compared to HT29 (MSS-CRC cell lines). Then, we 
investigate the levels of two important tumor 
suppressor genes: MLH1, key gene involved in the 
Mismatch Repair (MMR), whose 
loss/mutation/silencing is crucial in the 
establishment of the microsatellite instability; 
CDH1, coding for the E-cadherin protein, crucial for 
the cell-cell adhesion, antagonist of cell 
invasiveness, and well-known to be negative 
regulated by UHRF1 in prostate tumors [Babbio F, et 
al.; Oncogene, 2012]. According to the different 
levels of UHRF1, we observed good levels of CDH1 
and MLH1 in HT29, and no expression of both of 
them in RKO cells. 
 
4.2.2. UHRF1 overexpression correlates with DNA hypermethylation in CRC cell lines 
In order to compare the cell lines to what observed in the human specimens, we 
analyzed DNA methylation profile by using the same approach used for the 
histological specimens (pyrosequencing of LINE-1 and MS-MLPA of the same 34 
selected TSGs). 
 
Figure 4.7. Western Blot analysis of total 
protein extracts of RKO and HT29 cells. 
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DNA methylation, both at global 
level (LINE-1, pyrosequencing) 
and at specific sites (Gene 
promoter, MS-MLPA), is higher 
in RKO (MSI-derived) compared 
to HT29 (MSS-derived), 
according to the higher level of 
UHRF1 in this cell line (Figure 
4.8). In particular, the promoter 
of MLH1 gene, whose silencing is 
crucial to establish the MSI CRC, 
showed a prominent differential 
value in the Methylation Dosage 
Ratio (MR) obtained from the 
MS-MLPA analysis. In fact, RKO 
showed 0.9 MR comparare to 0.1 MR of HT-29 cells, with a cut-off to consider a 
promoter methylated of 0.2 MR (data not shown singularly). This site specific DNA 
hypermethylation was consistent with MLH1 silencing in RKO cells, as shown 
previously in WB analysis (Figure 4.7). 
 
Altogether these results showed that UHRF1 protein levels correlate positively to the 
DNA methylation levels in CRC cell lines, according to the in vivo observations. In fact, 
the two analyzed cell lines recapitulated well the features previously observed in the 
human samples. In order to evaluate the potential link between UHRF1 and the 
observed hyper-methylation we decided to manipulate the UHRF1 levels in vitro. 
Due to the interesting molecular patho-genetic features (MSI CRC model, CIMP-high, 
CIN-negative, BRAF-V600E, PI3KCA-H1047R) [Ahmed D., et al.; Oncogenesis, 2013], 
and the high levels of UHRF1 we selected the RKO cells for the further analysis.  
  
Figure 4.8. Summary DNA methylation data. Gene promoter 
methylation was measured by MS-MLPA analysis. LINE-1 
methylation, as surrogated of global methylation, was assessed by 
DNA pyrosequencing of 4 CpGs located in 5’UTR of LINE-1 sequences. 
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4.3. Evaluation of the effect of UHRF1 knock down on DNA methylation, 
gene expression and histone modifications in RKO cells 
In order to modulate the level of UHRF1, and evaluate the effect on DNA methylation 
patterns, genes expression and histone PTMs profile, we performed a transient 
silencing of UHRF1 by short interfering RNA (siRNA) in RKO cells.  
 
4.3.1. UHRF1 KD decreases DNA methylation levels in MSI cell model (RKO) 
To set up the transfection protocol, two different transfection reagents were used 
on RKO cells: Interferin (Polyplus) and RNAiMax (Life Techologies). Between them, 
the RNAiMax (together with siUHRF1 L ife Techologies, at 10nM, for 72h) gave us the 
best results both in term of cell viability, reproducibility and UHRF1 silencing.  
 
We evaluated the efficiency of the UHRF1 silencing by WB analysis (Figure 4.9a). 
After the initial set up, we were able to obtain a reproducible know down of 95% in 
every experiment. Then, we investigate the impact of UHRF1 depletion on DNA 
methylation by pyrosequencing analysis of MLH1 and CDH1 promoters and of 5’UTR 
LINE-1 sequences, as surrogated of global methylation. UHRF1 knock down induced 
an overall decrease in DNA methylation (Figure 4.9b) both at global level (LINE-1) 
and at gene promoters of MLH1 and CDH1. LINE-1 showed a DNA de-methylation of 
32.17% (± 0.77%), maintaining a residual methylation of 38.10% (± 0.35%). MLH1 
Figure 4.9. a) WB analysis of total protein extracts from scramble and siUHRF1 RKO cells, after 72h from transfection. 
B) Histogram of the pyrosequencing results; LINE-1 methylation, as surrogated of global methylation, was assessed by 
DNA pyrosequencing of 4 CpGs located in 5’UTR of LINE-1 sequences. MLH1 and CDH1 methylation was assessed by 
DNA pyrosequencing of respectively 5 and 6 CpGs located in their promoters. All percentages derived from an average 
between two independent biological replicates. Significance has been calculated using Anova. p < 0.0001 
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showed a decrement in DNA methylation of 43.08% (± 1.24%), maintaining a residual 
methylation of 48.47% (± 0.47%). CDH1 showed a DNA de-methylation of 34.86% (± 
1.68%), maintaining a residual methylation of 43.33% (± 0.05%). 
 
Subsequently, we analyze the DNA methylation levels in the same panel of 34 
oncosuppressor genes analyzed by MS-MLPA assay in the human samples. We 
observed an overall decrease in DNA methylation (Figure 4.10), upon UHRF1 
silencing, almost in all the analyzed promoters. Further, MS-MLPA data of MLH1 
promoter confirmed the Pyrosequencing result (shown previously in Figure 4.9b), 
assessing the differential methylation at 43.42%. Altogether these data led us to 
hypothesize that in RKO cell lines, the high levels of UHRF1 could mediate the 
transcriptional repression of these TSGs, including CDH1 (see pyrosequencing in 
Figure 4.9b). In this scenario, the modulation of UHRF1 should be sufficient, not only 





Figure 4.10. MS-MLPA analysis performed in RKO cells after UHRF1 silencing. The table on left reports the DNA 
methylation values assessed for the promoters of 34 tumor suppressor genes, considered crucial for tumorigenesis of 
CRC. Statistical significance was calculated by Anova test.
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4.3.2. UHRF1 silencing is not sufficient for the re-expression of CDH1 and MLH1 genes 
in RKO cells 
In order to verify whether UHRF1 depletion is sufficient to induce a transcriptional 
re-expression of CDH1 and MLH1 genes, we performed a WB and PCR on UHRF1 KD 
RKO cells, investigating respectively proteins and mRNAs levels. 
The WB analysis (Figure 4.11a) confirmed that the UHRF1 protein level was strongly 
reduced in the silenced UHRF1 sample (siUHRF1) compared to the control 
(scramble). Nevertheless, this decrement was not sufficient to observe a re-
expression of CDH1 and MLH1 proteins. In semi-quantitative PCR (Figure 4.11b), we 
analyzed changes in mRNA expression levels of UHRF1, CDH1 and MLH1, upon 
UHRF1 silencing (after 72h from transfection). UHRF1 mRNA level, as expected, was 
lower in siUHRF1 sample compared to control (after 34 cycles of PCR amplification). 
Regarding CDH1 and MLH1, there was not a re-expression either at transcriptional 
level (after 34 PCR cycles). 
These results showed that, even if UHRF1 KD significantly reduced the DNA 
methylation on CDH1 and MLH1, it was not sufficient to induce their re-expression, 
probably due to other convergent mechanisms of transcriptional repression on these 
promoters (see below for more details). 
4.11. a) WB analysis of total protein extracts from scramble and siUHRF1 RKO cell lines. b) Semi-quantitative PCR 
analysis of mRNA (cDNA) expression levels of UHRF1, MLH1 and CDH1. GAPDH was used as reference gene. 
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4.3.3. DNA de-methylation on LINE-1, CDH1 and MLH1 promoter regions is induced by 
the DNMT1 delocalization  
Since the relationship between UHRF1 and the DNA methyl-transferases, either of 
DNMT1 [Bostick M, et al.; Science, 2007] [Sharif J, et al.; Nature, 2007], or DNMT3A, 
DNMT3B [Meilinger D, et al.; EMBO reports, 2009] is 
well known, we investigated better the changes 
mediated by the UHRF1 depletion on these crucial 
epigenetic actors in RKO cells.  
In the attempt to elucidate the molecular basis of the 
strong DNA de-methylation previously observed, we 
performed a WB analysis on DNMTs protein levels in 
UHRF1 depleted RKO cells. UHRF1 KD did not induce 
any significant alteration in the protein levels of the 
DNA methyl-transferases (Figure 4.12). This result 
suggested that DNA de-methylation, observed in 
previous experiments, was not dependent on DNMTs 
protein degradation but probably was due to a 
delocalization of DNMTs on target foci. 
In order to validate our hypothesis and to establish 
whether UHRF1 knock down was impairing the 
DNMTs recruitment, we performed a Chromatin 
Immunoprecipitation (ChIP) analysis of the DNMTs (Figure 4.13) on LINE-1 5’UTR 
sequences and on MLH1 and CDH1 promoter regions. 
ChIP analysis showed a strong decrease of UHRF1 binding, as expected upon UHRF1 
knock down. The absence of UHRF1 impaired the DNMT1 recruitment to both 
specific gene promoters (MLH1, CDH1) and repetitive elements (LINE-1). This data 
was consistent with literature about the tight interaction between UHRF1 and 
DNMT1 [Bostick M, et al.; Science, 2007] [Sharif J, et al.; Nature, 2007], and strongly 
supported our hypothesis about DNMT1 delocalization as the major cause of DNA 
de-methylation observed in these same regions (see Figure 4.9b). DNMT3A showed 
a delocalization on MLH1 and a mild decreased binding on CDH1 promoter regions, 
while there was no decrease on LINE-1 sequence. DNMT3B, on the other side 
revealed a clear increased binding to all analyzed regions, except for CDH1 promoter 
4.12. WB analysis of total protein 
extracts from scramble and siUHRF1 
RKO cell lines, after 72h from 




(in particular amplicon 1), in which DNMT3B seemed almost stable, starting from an 
already higher level in the control. 
These observations could be due to the fact that DNMT3A/3B does not require the 
presence of interacting-chromatin-actors (e.g. HP1, MeCp2, EZH2, UHRF1, HDAC1, 
PCNA), or particular histone modification profiles, to corroborate DNMT1 in its 
ongoing participation in DNA methylation maintenance [Jones PA and Liang G; 
Nature Rev. Genet., 2009]. As expected, we denoted a complete absence of all the 
investigated actors on the promoter region of the Actin gene. 
Figure 4.13. ChIP analysis on DNMTs, investigating their chromatin localization on LINE-1 5’UTR sequences and on 
MLH1 and CDH1 promoter regions. Images on left shows the PCR products starting from ChIP samples. Actin gene was 
used as negative control. Bar-plot on the right shows the relative densitometric analysis of detected PCR bands. 
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4.3.4. PRC2, via H3K27me3 deposition, promotes convergent mechanisms of 
transcriptional repression on LINE-1, CDH1 and MLH1 promoters  
In the attempt to better investigate the chromatin profile of the analyzed regions 
and to better elucidate the involved molecular mechanisms, we performed a ChIP 
(on the same regions of LINE-1, MLH1 and CDH1) of H3K9me3, H3K27me3, and 
H3K4me3 [Kouzarides T; Cell, 2007]. H3K9me3 is a well-known repressive, generally 
heterochromatic, histone mark related to UHRF1, in particular it is strongly 
recognized by TTD domain of UHRF1 [Cheng J, et al.; 2013; J Biol Chem] [Xie S, et al.; 
2012; J Biol Chem] [Rottach A, et al.; 2010; Nucleic Acids Res.]. Further, UHRF1 
mediates its deposition by the direct interaction with the histone-methyl-
transferases (HMTs) G9a (mono- e di-methylation of H3K9) and Suv39H1 (try-
methylation of H3K9) [Kim JK, et al.; Nucleic Acids Research, 2009] [Meilinger D, et 
al.; EMBO reports; 2009] [Babbio F, et al.; Oncogene, 2012]. H3K27me3 is a 
chromatin repressive mark deposed by EZH2, part of Polycomb Repressive Complex 
2 (PRC2), mainly involved in the gene silencing during the normal cell commitment, 
and often found mis-distributed on oncosuppressor CpG island (CGI) in cancer [Richly 
H, et al; Cell Death and Disease, 2011] [Schuettengruber B, and Cavalli G; 
Development, 2009]. We previously showed that in prostate cancer cells, EZH2 acts 
in an independent and convergent mechanism from UHRF1 to silence TSGs [Babbio 
F, et al.; Oncogene, 2012]. On the contrary, H3K4me3 is a chromatin active mark, 
deposed by a several redundant HMTs (e.g. PRDM9, Set9, MML1, ASH1), well-known 
to regulate transcriptional activation by promoting the binding of positive 
transcription factors [Li H, et al; Nature, 2005], and blocking negative ones [Nishioka 
K, et al.; Nature 2006]. 
Despite the de-localization of DNMT1 and the de-methylation observed previously, 
we did not observe a re-expression of MLH1 and CDH1 gene. These data suggested 
that their promoter regions could be regulated by several convergent mechanisms 
of transcriptional repression. We performed a ChIP analysis on hPTMs in order to 
verify the local chromatin state of our interesting regions (Figure 4.14). 
We observed a strong alteration in chromatin profile of histone marks, upon UHRF1 
silencing. In particular, we detected the strong decrease of H3K9me3 in the siUHRF1 
samples compared to controls, in accordance with literature [Babbio F, et al.; 
Oncogene, 2012]. The co-occurrence in the control samples of H3K9me3 and a weak 
signal of H3K4me3 was not in contrast with the UHRF1 binding, denoted previously 
Results 
56 
in Figure 4.13. In fact, it has been reported that UHRF1-PHD domain is able to 
recognize the histone H3 tails also in presence of H3K4me3 (with H3K2unmodified), 
linking UHRF1 to the repression of euchromatin [Rajakumara, et al.; Mol. Cell, 2011]. 
We observed a mild increase of H3K4me3 on CDH1 and MLH1 promoter regions, and 
a considerable gain on LINE-1 sequences, probably as a consequence of the 
H3K9me3 loss, in accord with the activity of some H3K4 methyl-transferases, like 
PRDM9 [Wu H, et al.; Cell Report, 2013]. In the control sample (scramble) we 
Figure 4.14. ChIP analysis of histone PTMs (H3K9me3, H3K27me3, and H3K4me3) on LINE-1 5’UTR, MLH1 and CDH1 
promoter regions. Left panels: PCR of the analyzed promoters. Actin gene was used as control. Number in parentheses, 
close to gene names, referred to distinct primer sets. Right panels: Densitometric analysis of detected PCR bands. 
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observed a weak signal of H3K4me3 and the strong H3K9me3 presence. It is well-
known that other SET domain HMTs, like ASH1, part of the Polycomb Group protein 
(PcG), shows the ability to methylate different substrates concurrently, like H3K4, 
H3K9, H3K36 and H4K20 [Beisel C, et al.; Nature 2002]. ASH1, together with TRX-N-
terminal, part of the transcriptional activation Trithorax protein group (TrxG), are not 
incompatible with repressive marks, like H3K9me3, or H3K27me3. Therefore, in our 
model, the presence of H3K27me3 (permanent or mild increased, regardless of 
UHRF1 KD), laid by EZH2, was consistent with a condition, reported in literature, 
called ‘‘balanced’’ state, in which PcG and TrxG proteins act simultaneously or at 
least in rapid alternation from active to repressive chromatin state, in concert with 
other positive and/or negative epigenetic regulators [Schwartz YB, et al.; PLOS 
Genetics, 2010].  
It was worthy of note that LINE-1 sequences showed a slightly different chromatin 
profile. In control samples, they showed a strong presence of H3K9me3, in relation 
to UHRF1 and hyper-methylated DNA (very similar to normal peripheral blood cells 
[Baba Y, et al.; Mol. Cancer, 2010]). UHRF1 depletion caused strong alteration of their 
chromatin configuration: in fact, on one side there was a considerable gain of 
H3K4me3 that could lead to an increased transcriptional accessibility, and on the 
other side, the gain of mild H3K27me3 attested a sort of compensation repressive 
mechanism leading to a not complete re-expression of these sequences, as 
confirmed in qPCR analysis (data not shown) and RNA-seq data (see 4.4.2 paragraph 
below for details). Eventually, Actin promoter, as expected, was mainly characterized 
by H3K4me3 presence. 
 
Recapitulating all these data, we observed that UHRF1 knock down induces a 
significantly decrease of DNA methylation both at global level (LINE-1) and at tumor 
suppressor gene promoters (MS-MLPA and specific Pyrosequencing of MLH1 and 
CDH1), without affecting the DNMTs levels (WB analysis). ChIP experiments 
demonstrated that UHRF1 KD impairs the DNMT1 recruitment to both specific gene 
promoters (MLH1, CDH1) and repetitive elements (LINE-1). Moreover, we observed 
that the lack of UHRF1 induces an increased binding of DNMT3B that can explain the 
residual DNA methylation. Regarding the hPTMs profile, UHRF1 knock down strongly 
decreased H3K9me3 presence on MLH1, CDH1 and LINE-1 and mild increased 
H3K4me3 on the same promoters. Despite all these epigenetic changes, toward a 
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more open transcriptional accessibility, we did not observe a re-expression of the 
analyzed genes, probably due to the H3K27me3 maintenance through the PCR2. 
 
Altogether these intriguing data stimulated us to evaluate the impact of UHRF1 KD 
at genome wide level, both on DNA methylation and on transcriptome. To address 
this aim we performed a Reduced Representation Bisulfite Sequencing (RRB-seq) 




4.4. Genome wide analysis of the effect of UHRF1 silencing on the 
methylome and the transcriptome  
In order to evaluate the impact of UHRF1 KD on DNA methylation and on the 
transcriptome profile we performed a RRB-seq analysis, coupled to RNA-seq. This 
analysis, in collaboration with Prof. Alessandro Weisz (Lab of Molecular Medicine & 
Genomics, University of Salerno, Italy), would allow us to enlighten the involvement 
of UHRF1 on the loci/genes that are differential methylated and differential 
expressed.   
 
4.4.1. UHRF1 KD decreases DNA methylation at genomic level in RKO cells 
To evaluate the involvement of UHRF1 on the genome wide DNA methylation we 
prepared, from both UHRF1 silenced (siUHRF1) and control (scramble) RKO cells. 20 
µg of DNA each replicate, and three biological independent replicates were used for 
the RRB-seq analysis.  
RRB-sequencing analysis confirmed the overall decrease of the DNA methylation 
observed by pyrosequencing analysis upon UHRF1 silencing (Figure 4.15). In 
particular, we observed that the Differential Methylated CpGs (DM CpGs) are about 
33.3% (1,584,975 CpGs) of the total identified CpGs, assessed around 4.8 million per 
each sample (with RC>10). As expected, 99.92% (1,583,862 CpGs) of the DM CpGs 
identified are hypo-methylated (Figure 4.15b, table upper right). Furthermore, we 
analyzed the percentage of the methylation detected in each cytosine in a CpG 
context (Figure 4.15a, and histogram in 4.15b middle-bottom). All the control 
samples showed a similar distribution of the total CpGs between the “fully 
methylated” status (an average of 26% of identified CpG) and the “not-methylated” 
status (an average of 27% of identified CpGs), in a sort of “bimodal distribution”. All 
the siUHRF1 samples showed a strong de-methylation, as already reported by raw 
numbers in the table of Figure 4.15b, but interestingly the hypo-methylation 
regarded mainly the CpGs that resulted fully methylated in the controls. Surprisingly, 
only less than 3% of CpGs showed a complete de-methylation to a “not-methylated” 
status, even if both UHRF1 and DNMT1 were de-localized in UHRF1-depleted cells 
(Figure 4.13). Thus, the majority of the “fully methylated” CpGs resulted not 
homogeneously demethylated giving rise a heterogeneous methylation status of the 
silenced population. This data was in accord with the pyrosequencing analysis of 
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LINE1, CDH1 and MLH1, in which, upon UHRF1 depletion, DNA methylation levels 
assessed to roughly the half of initial values. An explanation to this residual DNA 
methylation could reside in the enhanced localization of DNMT3B both at global level 
and on gene promoters, as observed in our ChIP experiment in Figure 4.13, in 
accordance with BRAF mutation in RKO cells [Jeong S, et al.; Mol Cell Biol., 2009] 
[Fang M, et al.; Mol. Cell, 2014]. 
In order to classify better the distribution of identified CpGs and Differential 
Methylated CpGs along the genome we clustered them into well-known categories 
(Figure 4.16): on one side the distribution related to the CpGs organization (Shore, 
CpG island, Others), and on the other side the distribution related to annotated 
organization of the genes (Promoter, Exon, Intron, Intergenic). Since RRBS analysis 
have the peculiarity to enrich the CpG islands (CGI), we observed, as expected, that 
the 51% of the identified CpGs were localized at CGI regions, and the 41% of CpG are 
found into promoters. Nevertheless, focusing only on the Differential methylated 
(DM) CpGs, they are distributed equally all over the genome. In fact, even if the 
identified CpGs fell in CGI and promoter regions, the majority of DM CpGs are located 
in not-CGI (Others) sites, as intergenic or intronic regions.   
Figure 4.15. a) Histogram of the % CpG methylation. Control sample (scramble, upper plot) versus silenced UHRF1 
(siUHRF1, bottom plot) shows the strong de-methylation of the “fully methylated” CpG in RKO cells. b) The table in 
the upper part reports raw number of CpG identified. In the middle-bottom part are reported all the other histogram 
of the independent biological replicates. 
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These data were in accord with the role of UHRF1, together with DNMT1, in the DNA 
methylation maintenance. Moreover, it has been shown that UHRF1 mainly localized 
at the heterochromatic regions characterized by high levels of DNA methylation. Our 
data showed that UHRF1 depletion reduced the DNA methylation of the “fully 
methylated” regions, generally representative of heterochromatic regions, such as 
intergenic regions. 
However, we observed an important percentage of DM CpGs located in the 
promoter regions (16%) and in body of genes (Exon 15% + Intron 35%). Therefore, 
since the analyzed samples derived from a colorectal cancer cell lines, well-known to 
show an aberrant hyper-methylation of CGIs and promoters, as demonstrated 
before (by MS-MLPA and Pyrosequencing analysis), we performed a preliminary 
bioinformatic analysis in order to investigate the levels of the promoter methylation 
of CDH1 and MLH1. In particular, we assessed the methylation values of respectively 
4 and 5 CpG of CDH1 and MLH1 promoters, in the same regions investigated 
previously by MS-MLPA and pyrosequencing analysis. The analysis of CDH1 showed 
a de-methylation of 39% among the 4 analyzed CpGs (Figure 4.17). MLH1 showed a 
milder de-methylation (29%), compared to previous analysis (Figures 4.10 and 4.9b). 
  
Figure 4.16. Pie Charts of classification and genomic distribution of CpGs identified in RRBS on RKO cells. Categories 




We investigated the LINE-1 family in the genome datasets, and we observed a 
consistent decrease in DNA methylation (data not shown), as expected relying on 
the fact that 99.92% of CpGs are hypo-methylated. 
 
Since we observed this strong effect on DNA methylation we decided to investigate 
better the role of this loss of DNA methylation on the transcriptome. To address this 
aim we performed an RNA-seq analysis in RKO cells (scramble and siUHRF1). 
Figure 4.17. RRB-seq. Percentage of methylation of 4 CpGs on CDH1 promoter, as average of 3 independent biological 
replicates. The values are normalized to the respective coverage of each cytosine detected in the RRB-sequencing. 
Statistical significance was calculated by Anova test. (*) means p < 0.05, (**) means p < 0.002. 
Figure 4.18. RRB-seq. Percentage of methylation of 5 CpGs on MLH1 promoter, as average of 3 independent biological 
replicates. The values are normalized to the respective coverage of each cytosine detected in the RRB-sequencing. 
Statistical significance was calculated by Anova test. (*) means p < 0.05, (**) means p < 0.005, (***) means p <  0.001. 
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4.4.2. UHRF1 silencing is not sufficient for the re-expression of CDH1 and MLH1 
genes, and LINE-1 sequences in RKO cells 
To evaluate the impact of the UHRF1 KD on the transcriptome, we perform a RNA-
seq analysis in siUHRF1 RKO cells and relative control (scramble RKO cells). The RNA-
seq results were used to both determine which pathways are affected by UHRF1 KD 
(see paragraph 4.4.3.) and to investigate specific gene expression. 
In order to explore the expression of specific genes, we compared the RPKM values. 
These values have been already normalized for the length of the transcript and they 
can be used to directly compare gene expression. Nevertheless, the DeSeq approach 
used for the calculation of the differentially expressed genes doesn’t allow to extract 
information from the genes that have 0 reads in one of the 2 samples, either siUHRF1 
or control.  
First, we investigate the levels of the major enzymes involved in the DNA methylation 
and demethylation pathways (Figure 4.19a). The analysis showed that only UHRF1 is 
significantly decreased, mainly confirmed the qPCR results. Moreover, neither TET2 
or TET3 were affected by UHRF1 KD. We could not analyze TET1 because in one or 
both of the two conditions TET1 had 0 reads. These results support the idea the 
changes in the DNA methylation profile are primarily induced by a reshuffling (i.e. 
DNMT1 delocalization and DNMT3B repositioning, as observed by ChIP assay) of the 
methylator complexes and not due to an overall decrease of the apparatus.  
Figure 4.19a. RPKM values of the major proteins involved in the DNA methylation pathway. Statistical significance was 
calculated by Anova test. (****) means p < 0.0001. 
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Then, we decided to investigate the level of the enzymes involved in the histone 
modification pathway (Figure 4.19b). The RNA-seq analysis showed that only the 
HDAC1 was significantly increased by the UHRF1 KD. Even if this data seemed to 
counteract the overall opening of the chromatin, none of the other analyzed factors 
were changed in the UHRF1 silenced cells. These results perfectly matched with the 
SILAC bulk analysis (see later in the Results) that showed that the UHRF1 KD did not 
significantly affect any histone modifications overall.  
Furthermore, we checked the levels of CDH1 and MLH1. According to what we found 
by qPCR and WB, CDH1 did not have any reads in one or both the samples and 
therefore the DeSeq analysis did not show any results for it. MLH1 showed an 
average of 8 reads in total in both the siUHRF1 and the controls, with no significant 
changes between the two conditions (data not shown). 
 
The evaluation of the differential expression of the LINE-1 sequences was more 
complicated. In fact, the algorithm used for the alignment automatically discharge 
the repetitive reads (i.e. reads that map in more than one locus on the genome). This 
is based on the assumption that the “real transcripts” should be uniquely mapped. 
This is not true for the LINE-1 since they are repetitive elements, and even if most of 
them resulted mutated, the level of the mutation is not enough to uniquely map 
them on a reference genome. This is not an easy bioinformatics problem to solve. At 
the moment, there are not available pipelines that can take this problem into 
account, and lower the threshold for the uniquely mapped reads will result in an 
Figure 4.19b. RPKM values of the major proteins involved in the Histone modification pathway. Statistical significance 
was calculated by Anova test. (****) means p < 0.0001. 
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overall misalignment. Nevertheless, we were able to 
detect some of them by using a previously developed 
algorithm [Criscione SW, et al.; BMC Genomics., 2014]. 
We found 131 LINE-1 sequences with more than 1 read 
mapped (Figure 4.20). None of them showed a fold 
change greater or smaller than 0.5. 
 
We can conclude that even if we observed great 
changes on both methylation and chromatin status, 
these changes were not sufficient to change the 






Figure 4.20. Heat map of the 131 
identified LINE-1 sequences. 
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4.4.3. UHRF1 KD interferes with cell proliferation, cell growth, DNA damage and DNA 
repair 
In order to evaluate the effect of UHRF1 depletion on the transcriptome, we 
performed a RNA-seq analysis on three independent biological replicates. After 
sequencing we follow a DESeq pipeline [Anders S, et al.; Genome Biol., 2010]. We 
obtained 1810 differential expressed transcripts (DE), corresponding to 512 genes 
up-regulated and 201 down-regulated with a Fold-Change (FC) higher or lower that 
1.5 (Figure 4.21). 
The fold change of the up-regulated genes spanned from 1.5 to 222.83 
(corresponding to a log2FC between 0.58 and 7.80). The FC of the downregulated 
genes spanned from -1.5 to -3.65 FC (corresponding to a log2FC between -0.58 and 
-1.87). We analyzed RNA-seq data by Ingenuity Pathway Analysis (IPA), in the 
attempt to identify the main pathways in which UHRF1 was involved. IPA showed 
that UHRF1 KD interfered with several important pathways, among others cell 
proliferation, cell growth, DNA damage and DNA repair, cell cycle and Wnt signaling 
(Figure 4.22). Nevertheless, we observed a coherent induction of the whole pathway 
only in the TFG  signaling pathway. Surprisingly, upon UHRF1 depletion, we 
observed an increase in genes belonging to the cell growth and proliferation 
ontological cluster.  
  
Figure 4.21. DESeq bioinformatic analysis of RNA-seq data. The number of differential expressed transcript (DE genes) 
are assessed with a p-value adjusted lower of 0.05. UP- and DOWN-regulated genes are found with a Fold Change (FC) 




Figure 4.22. Ingenuity Pathway Analysis (IPA) of cell growth & proliferation pathways related to colorectal cancer. In 
read are delineated the up-regulated genes and in green the down-regulated ones, upon UHRF1 KD in RKO cells. 
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However, we observed a downregulation in the genes belonging to the cell cycle 
ontological cluster. These data agreed with our previous reports in which we showed 
that UHRF1 decreased cell proliferation [Babbio F, et al.; Oncogene, 2012]. 
Altogether these antithetical observations could be explained, at least in part, by the 
fact that UHRF1 is not a transcription factor or a repressor with specific target 
sequences. In fact, at the moment, there is no a consensus sequence that could drive 
the localization of UHRF1 to the target foci, rather it is able to recognize a plethora 
of epigenetic signatures, from DNA modifications to histone PTMs. It is plausible that 
its recruiting is cell-type and context dependent. Therefore, UHRF1, related to the 
possible epigenetic conditions, could be localized on different targets, activating or 
inhibiting several pathways. 
 
Since the UHRF1 KD generated a clear strong de-methylation and the majority of the 
DE genes were up-regulated, we decided to investigate better the possible 
correlation between differential methylated and differential expressed genes. 
 
4.4.4. DNA de-methylation correlates to transcriptional upregulation of specific loci  
The RRBS and RNA-seq data prompted us to investigate the possible relationship 
between the genome wide methylation profile and the transcriptome. In order to 
enlighten the differential methylated and differential expressed (DM and DE) 
loci/genes, we integrated the two datasets obtained by RRBS and RNA-seq, coupling 
the genome wide methylation profile to the transcriptome. 
In particular, we intersected the DM CpGs (with cut-off 20 in differential methylated 
value, and q-value < 0.05) with the DE transcripts (with cut-off 0.5 log2(FC), and p-
value-adjust < 0.05). This analysis showed the presence of a cluster of differential 
hypo-methylated (Hypo-DM) CpGs harbored in the up-regulated (Up-DE) transcripts 
(Figure 4.23a, in green). The Hypo-DM CpGs, linked to Up-DE transcripts, were 
distributed in different genomic annotated loci (Figure 4.23b), with preference to 
“Intron” and “Promoter-TSS”. However even if this finding was interesting, we noted 
that this analysis is un-related to transcript integrity, or alternative transcript of the 
same gene, or antisense-transcript harbored in the same loci. This resulted in a 
redundant number of genes involved in each annotated locus (Figure 4.23b, number 
in brackets in the table), due to the possibility that one CpG has an Ensembl genomic 
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annotation related to a specific “Promoter-TSS” of one transcript, but it has also can 
be annotated in the “Intron” of a second transcript that nests the first one. 
Moreover, the Hypo-DM CpGs, linked to Up-DE transcripts (47,222; Hypo_Up, green 
in scatter-plot and table of Figure 4.23a/b) represented less than 3% of total hypo-
methylated CpG identified in RRBS (1,583,862; Figure 4.15b, upper table). 
Intriguingly, this observation resulted in the fact that the 97% of hypo-methylated 
CpGs identified are not related to transcript regulation (96.62% including the 
Hypo_Down, blu in scatter-plot and table of Figure 4.23a/b), in perfect accord with 
our previously reported finding about the hypo-methylation of CDH1, MLH1 and 
LINE-1 loci, that not present any important transcriptional alteration. It was not 
clarified if Hypo_Up loci are located to particular chromatinic cluster that allows the 
up-regulation of the related genes. Further investigations are necessary also in order 
to spanning the Hypo-DM CpGs on the Up-DE transcripts to better correlate and to 
statistically calculate this intersection clustering. 
The genome-wide analysis confirmed the overall DNA hypomethylation mediated by 
UHRF1 silencing, both on LINE-1 and on specific gene promoters. Interestingly, about 
99,9% of DM CpGs were hypo-methylated, underlyng the pivotal role of UHRF1 in 
the DNA methylation maintenance. UHRF1 KD interfered with several important 
pathways, among others cell proliferation, cell growth, DNA damage and repair, cell 
cycle and Wnt signalling. Coupling the DM CpGs with the DE transcripts we showed 
that, even if there is cluster of genes that are hypo-methylated and up-regulated, 
these transcripts represented only the 3% of the hypo-methylated CpGs. This data 
Figure 4.23. RRBS and RNA-seq intersection analysis. a) Scatter-plot shows the distribution of CpGs differentially 
methylated (DM), comprehended in differentially expressed (DE) transcripts. b) The table shows the number of 
differently methylated CpGs found in the different genomic annotation, as described bottom. In parenthesis are 
indicated the number of genes involved, that harbor DM CpGs in own transcripts. 
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was perfectly consistent with our previous finding about CDH1, MLH1 and LINE-1 
loci, that showed a strong hypo-methylation but neither important transcriptional 
alteration, probably due to their epigenetic chromatin profile, as observed by ChIP. 
However, these analyses were not sufficient to elucidate the role of the DNA 
methylation in the regulation of these specific loci/genes, altered upon UHRF1 





4.5. Investigate the effect of UHRF1 silencing on ubiquitination of histone 
tails  
The data obtained by ChIP assay together with previously published evidences on 
UHRF1 ubiquitination activity [Qin W., et al; Cell Research, 2015] led us to 
hypothesize that the chromatin rearrangements, observed upon UHRF1 KD, could be 
mediated by the lack of H3K18ub seated by UHRF1 RING. In the attempt to verify 
this hypothesis and to better elucidate the involvement of UHRF1 in specific 
ubiquitination of histone tails, we performed a SILAC LC-MS/MS on RKO cells after 
siUHRF1. Eventually, the LC-MS/MS (SILAC) analysis would allow us to couple 
ubiquitination profile of hPTMs to genome wide methylation and transcriptome 
profile. 
 
4.5.1. Design and production of a monoclonal antibody against the H3K18ub 
As mentioned before, we recently published that UHRF1 ubiquitinates K18 of histone 
H3 by its RING domain, harboring a well-known E3 ubiquitin ligase activity [Citterio 
E, et al.; Mol. Cell. Biol., 2004] [Jenkins Y, et al.; Mol. Biol. of Cell, 2005] [Nishiyama 
A, et al.; Nature, 2013]. Furthermore, H3K18ub is essential for the maintenance of 
DNA methylation, enabling methylation activity of DNMT1, through interaction with 
its ubiquitin interacting motif (UIM) [Qin W., et al; Cell Research, 2015]. Altogether 
these evidences prompted us to design and produce a monoclonal antibody toward 
the monoubiquitinated lysine 18 of histone H3. This part of the project was carried 
out in collaboration with Dr. Mario Cinquanta (Cogentech, Campus IFOM-IEO, 
Milano). 
We immunized 4 immuno-reactive mice with a synthetic peptide harboring the 
branched epitope of ubiquitinated lysine 18 on H3 histone tail (Figure 4.24a). The 
sera collected from mice bleeding samples, after 3 immunizations (Figure 4.24c) and 
5 immunizations (Figure 4.24d) were analyzed by ELISA assay. We tested the 
reactivity of each serum against the same immunization peptide and, as negative 
control, versus an identical H3 tail peptide synthetized without the branching for 
K18ub. All four animals responded positively to immunization, comparing immune-
reactivity of the sera against H3K18ub peptide (Figure 4.24, c and d) with the pre-
immune sera collected from the same mouse (Figure 4.24b). Furthermore, we 
observed a clear specific antibody response to H3K18ub peptide, compared to 
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control H3 tail peptide, showing a good performance in the titration of the diluted 
sera. In the second bleeding after 5 immunizations, we noted that the mouse 1 
started to show a considerable response to control H3 tail peptide not ubiquitinated 
(Figure 4.24d).  
We performed a second screening on total histone acids extract, from RKO and PC3 
cell lines, by Western Blot analysis. PC3 cells showed some preliminary interesting 
evidence in the Ubiquitination profile in total histone acids extract analyzed by 
classical LC-MS/MS (data not shown). WB analysis showed that the sera (re-
suspended in TBS-Tween-milk 4%, with 1:50 dilution), respectively from mouse 3 and 
4, and from mouse 1 and 2, are very similar in the immune response profile (Figure 
4.25). In particular, the sera form mouse 2, 3 and 4 showed a band at the expected 
Figure 4.24. a) Designed synthetic peptide harboring the branched epitope of ubiquitinated lysine 18 on H3 histone 
tail. b,c,d) ELISA assay representing the titration of pre-immune sera (b), 1st bleeding sera after 3 immunizations (c) 
and 2nd bleeding sera after 5 immunizations (d), collected from the 4 mice immunized with H3K18ub peptide (a). 
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molecular weight corresponding to mono-ubiquitination of histone H3 (around 
25KDa), especially on the PC3 histone extracts. 
After these first steps, we performed the generation of hybridoma cell lines secreting 
mAbs against H3K18ub, by fusion antibody-producing B cells, derived from the 
spleen of the immune-reactive mice (03 & 04 together), with a myeloma (B cell 
cancer). The hybridoma’s media was screened by ELISA analysis in the attempt to 
detect either the best clones and eventual some trans-reaction against H3-
unmodified or other ubiquitinated protein (i.e. EGFR-ub). In order to expand and to 
enrich cell lines secreting mAbs against H3K18ub, we performed sub-cloning process 
for the first four best hybridomas, identified by ELISA (data not shown). We 
compared the profile observed in the WB assay comparing the hybridomas signals, 
the expected molecular weight, and, the staining from commercial antibodies 
against anti-H3 and anti-Ubiquitin-Total. These analyses allowed us to identified four 
clones (TN13, TN12, TK7, TN0) that showed a good specificity (data not shown). 
 
In order to obtain the best candidate for further analyses, we purified, by IgG affinity, 
these 4 monoclonal sera. Considering the concentration, the efficacy and the 
previous ELISA, the best sera was the clone TN13-7. This clone was used for 
subsequent experiments. In order to test the specificity, we performed a histone 
extraction from HEK293T cells overexpressing H3-FLAG wild type and H3_FLAG K18A, 
bearing a point mutation in the K18 (Figure 4.26, upper panel). The goal in this 
experiment was to identify an alternative profile in WB analysis comparing H3-FLAG 
WT with H3_FLAG K18A histones. Unfortunately, the presence of endogenous H3 
(wild type) made indistinguishable the profile between the two samples (Figure 4.26, 
Figure 4.25. Western Blot analysis of total histone acids extract, from RKO and PC3 cells. As primary blotted antibodies 
we used the sera from mice 1 (S#1), 2 (S#2), 3 (S#3) and 4 (S#4), re-suspended in TBS-Tween-milk 4%, with 1:50 dilution. 
The expected molecular weight corresponding to mono-ubiquitination of histone H3 is around 25KDa. 
Results 
74 
upper panel, on right, lane 2 and 3). Nevertheless, comparing the anti-H3 and the 
anti-H3K18ub (subclone TN13-7), we were able to identify some corresponding 
protein bands, which probably represent mono-/di-/tri-ubiquitinated forms of 
histone H3. The serum recognized several protein bands, which probably correspond 
to the histone H3 variants and/or H3 poly-ubiquitinated or SUMOylated forms, 
containing at least one H3K18ub branching. Furthermore, we observed a strong 
discrepancy in the ubiquitination profile of histone acid extraction derived from the 
different cell lines, that showed an anti-H3K18ub (subclone TN13-7) profile much 
more simple in HeLa (data not shown) compared to RKO cells (see an example in 
SILAC experiment below). 
We tried to perform also an immunoprecipitation against H3-FLAG, with the specific 
resin Sigma, but the elution of the beads (containing α-FLAG Ab) induced the 
disaggregation of the light chain of the antibody that migrate, as expected, at 25KDa, 
as well as H3K18ub, causing the failure of this experiment (data not shown). To 
better characterize the specificity of our antibody α-H3K18ub and avoid the 
“contamination” of the endogenous H3, we are now designing the specific point 
mutations using the CRISPR/Cas9 technology. 
  
Figure 4.26. WB analyses for testing specificity of H3K18ub (clone TN13-7) on histone acid extraction. Histone 
extractions were performed on HEK293T cells overexpressing H3-FLAG Wild Type (lane 2) and H3_FLAG K18A (point 
mutation, lane 3). 
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4.5.2. UHRF1 KD induces alteration in H3 N-term-Tail ubiquitination  
The LC-MS/MS (SILAC) analysis allowed us to analyze the proteomic profile of hPTMs 
related, independent or antithetical to UHRF1, with particular regard to 
ubiquitination of histone tails. In the attempt to observe, in a quantitative manner, 
the differences in histone proteomic profiles, we chose the SILAC (Stable Isotope 
Labeling by/with Amino acids in Cell culture) approach coupled with a LC-MS/MS, in 
collaboration with Dr. Tiziana Bonaldi (IEO, Campus IFOM-IEO, Milano). This 
technique gave us the advantage to label two samples (scramble and siUHRF1) with 
different and specific amino acids (lysine and/or arginine), non-radioactive stable 
isotopes. In this way, the two samples, homogeneously pooled in ratio 1 to 1, can be 
analyzed in a single mass-spectrometry analysis, obtaining a quantitative LC-MS/MS, 
that allowed us to discriminate the different samples comparing the shifted peaks 
observed for control (Light isotopes) and siUHRF1 (Heavy isotopes). 
In order to prepare the biological sample for quantitative SILAC mass-spectrometry 
analysis, we incorporated stable isotope amino-acids specific for hPTMs profile 
analysis, by growing RKO cells in SILAC medium (K-0; R-10). We evaluate the 
complete incorporation through LC-MS/MS analysis on total extracts from RKO cells 
at the eighth population doublings in SILAC medium. The ratio between Heavy and 
Light peptides analyzed suggests that the incorporation obtained is at least 97,4% 
(data not shown). We proceeded in the preparation of sample for quantitative SILAC 
mass-spectrometry analysis, performing a histone acid extract relying on the yield of 
previous experiments. In the attempt to obtain at least 300µg of histone proteins for 
all the subsequent experiments, we performed an acid extraction on a pool of 140 
millions (70 millions Heavy & 70 millions Light cultured in SILAC medium) of RKO cells 
mixed with ratio 1:1 (Figure 4.27, upper left flowchart). We obtain 750µg of histone 
proteins. For the first experimental analysis, we perform a SDS-PAGE on a gradient 
precast acrylamide gel to ensure the better separation of protein between 15 and 35 
KDa. We loaded 15µg of histones per lane in order to identify the protein bands that 
coincide each other (analyzed with antibodies against H3 and Ubq-total) (Figure 4.27, 
upper right, WB and Coomassie). Subsequently each selected band (cut out in the 
Coomassie stained gel) was analyzed in LC-MS/MS following the well-established 
procedure of our collaborators [Soldi M., et al; Int. J. Mol. Sci., 2013]. Using the same 
protocol, we prepared an “in solution digestion”, and an “in gel bands digestion” 
using 10µg of total histones, to identify the overall hPTMs profile of RKO cells, after 
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siUHRF1 (Figure 4.27, upper left flowchart).  Regarding the “in gel bands digestion” 
analysis we observed a strong alteration of H3 tails ubiquitination. In particular, we 
identified two ubiquitinated residues, H3K18ub and H3K23ub, in accordance with 
published data [Nishiyama A, et al.; Nature, 2013] [Qin W., et al; Cell Research, 2015]. 
Interestingly, in the band #6, correspondent to the molecular weight of the mono-
ubiquitinated H3 (25KDa), we identified H3K18ub and H3K23ub that are present 
alternatively in the two different peptides. Furthermore, in the band #4, 
correspondent to bi-ubiquitinated H3 (35KDa), we observed only H3K18ub that 
realistically would be bi-ubiquitinated as a branched poli-ubiquitination (Figure 4.27, 
middle table). The SILAC quantitative analysis of identified peptides allowed us to 
observe a RATIO between the same peptides derived from scramble (Light) and 
siUHRF1 (Heavy) samples. Surprisingly this quantitative analysis showed no changes 
(RATIO H/L = 1.004) in H3K18ub in the mono-ubiquitinated peptides (band #6). On 
the other hand, in the bi-ubiquitinated peptides (band #4) we observed a strong 
increasing in the H3K18ub (RATIO H/L = 2.496), upon UHRF1 silencing. Meanwhile 
we discovered a decreasing (RATIO H/L = 0.760) in H3K23ub in the mono-
ubiquitinated peptides (band #6) (Figure 4.27, bottom table). 
Figure 4.27. Quantitative mass-spectrometry analysis LC-MS/MS (SILAC), performed on RKO cell 
(scramble/siUHRF1), showed strong alteration in the ubiquitinated profile of H3 histone tails, especially in band #6 
and #4, respectively correspondent to the molecular weight of the mono- and the bi-ubiquitinated H3. 
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In the “in solution digestion” analysis, we observed, as expected, mild or not changes 
in the global hPTMs profile (e.g H3K4me3, H3K9me3, H3K27me3), and we did not 
found ubiquitinated peptides detectable at global level. However, it is not possible 
to compare the results coming from the “in gel bands analysis” with the results 
coming from the “in solution”. In fact, the first has a higher sensibility compared to 
the second that is mainly used to compare great changes in the bulk amount of 
histones. The direct analysis of the bands allows the detect even low represented 
and rare histone modifications that can have a role in the control of the local 
organization of the chromatin. In our specific case the analysis of the bands allowed 
us to detect changes in the H3K18ub, while the bulk was not able to detect 
ubiquitinations at all. 
 
In order to better investigate these data, we performed a second analysis, loading 
30µg of histone per lane. The specific goal of this second experimental analysis was 
to verify the specificity of our new antibodies against H3K18ub, and to find other 
ubiquitinated residues that could be low represented in the sample (e.g. 
H2BK120ub) (Figure 4.28). This second mass-spectrometry analysis LC-MS/MS 
(SILAC), confirmed the strong alteration in the ubiquitinated profile of H3 N-terminal 
tails. Moreover, the identified bands by our new antibody against H3K18ub (clone 
TN13-7) showed a high-fidelity recognition of the H3 ubiquitinated tails (bands 7 and 
8-9, corresponding to mono and bi-ubiquitination, at 25KDa & 35KDa) (Figure 4.28, 
middle table). In fact, these bands, analyzed by mass-spect, showed to contain 
mainly the K18 mono or bi-ubiquitinated. In the band #8 e #9 was also detected the 
residues K23ub, belonging to a different pool of histones H3, mono-ubiquitinated in 
K23, that migrate, as expected, in the same molecular weight (25KDa) during 
electrophoresis.  Among the different bands analyzed (i.e. #1, #3, #4, #5, #6, #7, #9, 
#10, #11), corresponding to a detected signal in the blot with H3K18ub antibody, 
only the bands #4 and #11 showed a trans-reaction with histone H1 ubiquitinated. 
The band #10 probably showed a mild trans-reaction with unmodified-H3, and the 
band #1 with poly-ubiquitinated histone H3. Nevertheless, all of them were 
negligible, due to the totally different molecular weight. Last but not the least, the 
bands #2 and #8-9, corresponding to a detected signal in the blot with the 
commercial available H2BK120ub antibody (Active Motif), did not contain a 
detectable amount of ubiquitinated peptide of H2B, although the bands were in the 
expected molecular weight. In fact, it was detected the poly ubiquitination of 
Results 
78 
H2BK24ub/K25ub in band #2, and mono-ubq of H2A.ZK126 in band #9, that migrate 
in the same molecular weight during electrophoresis. These findings seemed to 
argue against the specificity of the H2BK120ub antibody, but these results could 
reflect high magnification of the signal due the WB. In fact, we observed a similar 
result also for the H3K18ub antibody.  
The RATIO between the peptides (Figure 4.28, bottom table), derived from scramble 
(Light) and siUHRF1 (Heavy), showed the same trend of the first analysis (Figure 
4.26). In fact, H3K18ub in the bi-ubiquitinated peptides (band #7) showed a strong 
increase (RATIO H/L = 2.539) and no, or mild changes in the mono-ubiquitinated 
peptides detected in the band #8 (RATIO H/L = 0.962, or 1.164 in the presence of 
Figure 4.28. Quantitative mass-spectrometry analysis LC-MS/MS (SILAC), performed on RKO cell (scramble/siUHRF1), 
showed strong alteration in the ubiquitinated profile of H3 N-terminal tails. Moreover, the identified bands by our 
new antibody against H3K18ub (clone TN13-7) showed a high-fidelity recognition of the H3 ubiquitinated tails (bands 
7 and 8-9, corresponding to mono and bi-ubiquitination at 25KDa & 35KDa). 
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K23ac) and #9 (RATIO H/L = 0.884). H3K23ub in the mono-ubiquitinated peptides, 
band #8 and #9, showed respectively a consistent decrement, upon UHRF1 silencing 
(RATIO H/L = 0.772 and 0.630). 
 
For the first time, we analyzed the role of UHRF1 in the modulation of histone 
ubiquitination in a tumor cell line. Differently to what observed in Embryonic Stem 
Cells [Qin W., et al; Cell Research, 2015], in RKO cells, the UHRF1 silencing induced a 
more complex pool of histone ubiquitination. All together these results shed a new 
light about the role of UHRF1 in the chromatin remodeling, in fact it is able to 
indirectly modulate the histone methylation profile by recruiting the histone 
methyltransferases on the specific loci, but also it directly alters the ubiquitination 














Colorectal cancer (CRC) represents one of the major leading cause of cancer death 
[Ferlay J., et al.; Int. J Cancer., 2015]. In CRC, genetic and epigenetic alterations are 
tightly connected and not mutual exclusive events, as well as in other tumor types, 
cooperating in its development and progression. Interestingly, in colorectal cancer 
aberrant methylation events are more common than point mutations [Lao VV and 
Grady WM; Nat. Rev. Gastroenterol. Hepatol., 2011]. This is the case of a subclass of 
sporadic CRC tumors, that is characterized by peculiar molecular features, the 
microsatellite instability (MSI) and the hypermethylation of CpG islands (CIMP). In 
this subclass, the hypermethylated of the promoter of MHL1 gene led to the 
inactivation of the mismatch repair (MMR) mechanism [Weisenberger DJ, et al.; Nat. 
Genet., 2006]. Even if some mechanisms have been elucidated, most of the effects 
of the interaction between genetic mutations and epigenetic alterations on the 
patient’s outcome are not clearly understood, due to their complexity [Wu C and 
Bekaii-Saab T.; Chem. Res. Pract., 2012]. 
In this context, this PhD project wants to shed light on the molecular involvement of 
UHRF1, as pivotal epigenetic actor in DNA methylation maintenance, in the 
modulation of the aberrant DNA methylation profile characterizing this subclass of 
CRCs. In fact, UHRF1 is a multi-domain “cross-talk” protein involved in epigenetic 
regulation [Bronner C, et al.; Biochem. Pharmac., 2013], coupling the preservation of 
histone-modification through the cell cycle with the maintenance of DNA 
methylation, orchestrating DNMT1 activity by deposition of H3K18ub [Qin W., et al; 
Cell Research, 2015] and ubiquitination of several lysines of H3 tail [Harrison JS, et 
al.; eLife, 2016]. UHRF1 is found over-expressed in numerous tumor types, and it is 
involved in gene silencing of several tumor suppressor genes (e.g. p16INK4A, MLH1, 
BRCA1, RB1, APC, CDH1, RARβ1, RARβ2, PSP94), mediating the heterochromatic 
switch through the recruitment of the several repressive proteins (DNMT1, HDAC1, 
Suv39H1, G9a) [Alhosin M, et al.; J. Exper. Clin. Canc. Res., 2011] [Babbio F, et al.; 
Oncogene, 2012] [Unoki, et al; Oncogene, 2004] [Xie S, et al.; J. Biol. Chem., 2012]. 
In colon cancer cells, we demonstrated that UHRF1 recruits Suv39H1 and DNMTs on 
specific gene promoters (e.g. PPAR , CDH1 and RARβ), mediating their epigenetic 
silencing [Sabatino L, Fucci A, et al.; Oncogene, 2012]. 
 
Relying on all these observations, our studies focused first of all in the 
characterization of UHRF1 immunohistochemical levels, in relation to DNA 
methylation levels, in a cohort of colorectal mucosa samples, composed by normal 
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mucosae (N =25), MSI CRCs (N =47), and MSS CRC samples (N =88). Beyond the well-
known association between UHRF1 high levels and CRC cancer progression [Sabatino 
L, Fucci A, et al.; Oncogene, 2012], our finding demonstrated, for the first time, a 
surprisingly correlation, among microsatellite CRCs, between UHRF1-high levels and 
the better patient’s outcome. In fact, UHRF1 was significantly higher in MSI-CRC 
samples, compared to MSS-CRCs, correlating with an overall DNA hypermethylation 
in MSI-CRCs both at genome-wide and at gene specific level, in accordance with the 
role of UHRF1 in DNA methylation [Bostick M, et al.; Science, 2007] [Sharif J, et al.; 
Nature, 2007]. 
This intriguing result prompted us to deepen the molecular mechanism that 
underlies this clinical phenomenon. Thus we decided to use two cell lines derived 
from MSI-CRC (RKO) and MSS-CRC (HT29), demonstrating that UHRF1 protein levels 
correlate positively to the DNA methylation levels, in accord to the in vivo 
observations. In order to investigate the potential link between UHRF1 and the 
observed hyper-methylation we decided to manipulate the UHRF1 levels in RKO 
cells, since they showed the coexistence of UHRF1 high level and of the interesting 
molecular pathogenic features (MSI CRC model, CIMP-high, CIN-negative, BRAF-
V600E, PI3KCA-H1047R) [Ahmed D., et al.; Oncogenesis, 2013]. 
 
Our studies, either with molecular methods (i.e. Pyrosequencing and MS-MLPA) and 
next generation sequencing (NGS) approaches (i.e. RRBS), demonstrated that UHRF1 
knock down induces a significant overall DNA hypomethylation in RKO cells. In fact, 
almost the totality of identified DM CpGs were hypo-methylated in RRBS analysis, 
affecting mostly the not-CGI sites (e.g. “fully methylated” intergenic or intronic 
regions), underlying the pivotal role of UHRF1 in the DNA methylation maintenance 
[Bostick M, et al.; Science, 2007] [Sharif J, et al.; Nature, 2007] [Arita K, et al.; Nature, 
2008] [Avvakumov GV, et al.; Nature, 2008] and in the heterochromatin integrity 
[Karagianni P, et al.; Mol. Cell. Biol., 2008] [Papait R, et al.; Mol. Biol. Cell., 2008]. 
Further, UHRF1 silencing induced a consistent de-methylation either in the specific 
promoter of MLH1 and CDH1 and in 5’UTR sequences of the repetitive element LINE-
1, considered as a surrogate of global methylation due to the high representation of 





Deeper analysis of all these crucial CRC-related regions, by ChIP assay, helped us to 
demonstrate that this strong de-methylation was induced by DNMT1 delocalization 
from promoter regions. In fact, the levels of all DNMTs are not affected by UHRF1 
KD, as observed either by WB, semi-qPCR and NGS approaches (RNA-seq, RPKM 
counting). Interestingly, focusing on DNMT3A/3B, already reported to interact with 
UHRF1 [Meilinger D, et al.; EMBO reports, 2009], we observed that only DNMT3A 
binding was impaired upon UHRF1 KD. On the contrary, DNMT3B revealed a clear 
increased binding on the promoter of CDH1, MLH1 and 5’UTR of LINE-1. However, 
this data is perfectly consistent with previous studies in which DNMT3B was 
positively correlated with CIMP CRCs [Nosho K, et al.; Clin Cancer Res, 2009], and 
was the final DNA-methylator-actor of a transcriptional repressor complex driven by 
phosphorylated MAFG in RKO cells [Fang M, et al.; Mol. Cell, 2014]. In fact, the model 
proposed by Fang et al. perfectly matched with our finding: BRAF mutation (V600E), 
present in RKO cells, promotes the transcriptional silencing of several TSGs 
promoters (including MLH1), due to increased BRAF/MEK/ERK signaling that induces 
an ERK-directed phosphorylation of MAFG at S124, which recruits the corepressor 
complex (BACH1, CHD8, and DNMT3B) on promoter regions. Moreover, further 
evidences sustain the released action of DNMT3A/3B from the UHRF1 related 
interacting-chromatin-actors (e.g. HP1, MeCp2, EZH2, HDAC1, PCNA, DNMT1). In 
fact, DNMT3A/3B displays a sort of “anchoring” with nucleosomes containing 
methylated CpG sites, in particular nucleosomes containing methylated SINE/LINE 
elements and CpG islands [Jeong S, et al.; Mol Cell Biol., 2009], without specific 
affinity to precise histone PTMs profiles, corroborating DNMT1 in their ongoing 
participation in DNA methylation maintenance, after the passage of the replication 
fork [Jones PA and Liang G; Nature Rev. Genet., 2009]. 
 
These observations, matched with our results, contributed to the first fundamental 
pivot of the molecular model that we suggest in this PhD Thesis: the lack of UHRF1 
and the subsequent de-localization of DNMT1 might simulate the passage of the 
replication fork, reinforcing the binding of DNMT3B to the promoters that show a 
residual methylation in the CpGs, contained in nucleosome rich regions, providing a 
plausible explanation of the not complete de-methylation, observed in “local” and 
“genome-wide” experiments. In fact, even if the DNA de-methylation observed upon 
UHRF1 silencing is particularly strong, Pyrosequencing/MS-MLPA and RRBS showed 
a residual or persistent DNA methylation. Moreover, RRBS, through the analysis of 
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the percentage of the CpG methylation all over the genome, clearly demonstrated 
that, upon UHRF1 KD, CpG methylation percentages did not assessed in an average 
clustering around “hemi-methylated” or totally “not-methylated” status, as 
expected in a context of cycling cells without correct DNMT1 localization and 
functionality, reinforcing our idea about the role of DNMT3B in this cell line. 
 
Since mis-regulation and over-expression of UHRF1 showed a well-known 
involvement in the disruption of euchromatic regions [Rajakumara E, et al.; Mol. Cell, 
2011], affecting especially key tumor suppressor genes in CRCs [Sabatino L, Fucci A, 
et al.; Oncogene, 2012], we investigated whether, in RKO, UHRF1 silencing might 
lead to a re-expression of TSGs. Unexpectedly, our studies on CDH1 and MLH1 genes 
demonstrated that, even if UHRF1 KD significantly reduced the DNA methylation on 
their promoters, this is not sufficient to induce their re-expression, either at 
transcriptional (semi-qPCR and RNA-seq, RPKM counting) and translational levels 
(WB analysis). Interestingly, despite the de-localization of DNMT1 and the strong 
demethylation, we do not observe the re-expression of LINE-1 sequences . 
These data suggested that several mechanisms of transcriptional repression could 
be convergent on their promoter regions, as previously published in another context 
[Babbio F, et al.; Oncogene, 2012]. In fact, ChIP analysis on CDH1, MLH1 and LINE-1 
promoter regions, demonstrated that UHRF1 KD strongly decreased H3K9me3 and 
mild increased H3K4me3 on the promoters. H3K9me3 is a histone mark usually 
strictly associated with UHRF1, which is able to recruit the specific H3K9 histone 
methyltransferase (e.g. Suv39H1, G9a) [Meilinger D, et al.; EMBO reports; 2009] 
[Babbio F, et al.; Oncogene, 2012], and to mediate the propagation and stability of 
heterochromatic profiles, in concert with DNA methylation [Xie S, et al.; J. Biol. 
Chem., 2012]. H3K4me3 is a chromatin active histone mark, deposed by a several 
redundant HMTs (e.g. PRDM9, Set9, MML1, ASH1), well-related to transcriptional 
activity [Li H, et al; Nature, 2005] [Nishioka K, et al.; Nature 2006]. Noteworthy, we 
observed the co-occurrence in the RKO cells (in control sample, scramble) of 
H3K9me3 and a weak signal of H3K4me3 in CDH1 and MLH1 regions. This data is not 
in contrast with UHRF1 binding, that is able to recognize, through its PHD domain, 
the histone H3 tails also in presence of H3K4me3 (with H3K2unmodified), linking 




Conversely UHRF1 silencing did not affect the presence of H3K27me3, deposed by 
EZH2, part of PRC2 (a transcriptional repressive Polycomb protein group, PcG), in the 
analyzed regions of CDH1 and MLH1, confirming the independence of this hPTM 
from UHRF1-related complexes (e.g. DNMT1, HDAC1, HMTs), as previously observed 
[Babbio F, et al.; Oncogene, 2012]. H3K27me3, is considered as the main histone 
mark of facultative heterochromatin [Dillon N.; Cell Biol.; 2004], involved in the gene 
silencing during the normal cell commitment and often found mis-distributed on the 
CGI of tumor suppressor genes in cancer [Richly H, et al; Cell Death and Disease, 
2011] [Schuettengruber B, and Cavalli G; Development, 2009]. It was worthy of note 
that in the RKO cells (in control sample, scramble) we identified the coexistence of 
strong H3K9me3, H3K27me3, and mild H3K4me3 in CDH1 and MLH1 gene 
promoters. In fact, this data was consistent with the chromatin profile called 
‘‘balanced’’ state, in which Trithorax protein group (TrxG) and Polycomb Group 
protein (PcG) act simultaneously or in rapid alternation from active to repressive 
chromatin state, in concert with other positive and/or negative epigenetic regulators 
[Schwartz YB, et al.; PLOS Genetics, 2010]. In these multi-protein complexes are 
counted some HMTs with peculiar ambiguous functionality: for instance, the HMTs 
SET-domain-containing ASH1 shows the ability to methylate different substrates 
concurrently, like H3K4, H3K9, H3K36 and H4K20 [Beisel C, et al.; Nature 2002], and 
is not incompatible with repressive marks, like H3K9me3 or H3K27me3, taking part 
of both PcG and TrxG protein complexes [Schwartz YB, et al.; PLOS Genetics, 2010]. 
Interestingly, LINE-1 sequences showed a slightly different chromatin profile. In RKO 
(control samples, scramble) they showed a strong presence of H3K9me3, in relation 
to UHRF1 binding and hyper-methylated DNA profile (very similar to normal 
peripheral blood cells [Baba Y, et al.; Mol. Cancer, 2010]), as expected due to their 
implication in constitutive heterochromatin. UHRF1 depletion caused strong 
alteration of their chromatin configuration, leading to a considerable gain of 
H3K4me3, with a mild novel onset of H3K27me3, resulting in the so-called bi-valent 
chromatin state [Richly H, et al.; Cell Death and Disease, 2011]. 
 
This novel onset of H3K27me3 in LINE-1 sequences, together with stable or increased 
presence of this hPTM in the promoter regions of CDH1 and MLH1, led us to 
formulate the second fundamental pivot of the molecular model delineated in this 
PhD Thesis: even if UHRF1 depletion results in a severe chromatin rearrangement 
from a strongly repressed chromatin state (H3K9me3 rich) toward a more open 
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transcriptional accessibility (H3K4me3 enrichment), the stable or mild gain of 
H3K27me3 established a sort of compensative-repressive mechanism leading to the 
observed not re-expression of CDH1, MLH1 and LINE-1 loci. Interestingly, in contrast 
with previous report about UHRF1 depletion and TSGs re-expression [Alhosin M, et 
al.; J. Exper. Clin. Canc. Res., 2011] [Babbio F, et al.; Oncogene, 2012], we 
demonstrated that in RKO, characterized by MSI-high and CIMP-positive 
pathogenetic features, PRC2 plays a key role in the maintenance of a chromatin 
repressive state, probably driven by the epigenetic instability underlying this CRC 
subclass [Grady WM, and Carethers JM; Gastroenterology, 2008], acting in concert 
with DNMT3B that cooperate to maintain a persistent DNA methylation on these 
loci, even after UHRF1 depletion and subsequent de-localization of DNMT1. 
 
Our finding in ChIP analysis, and the previously published evidences about the crucial 
importance of UHRF1 ubiquitination activity in orchestrating DNMT1 functionality 
[Qin W., et al; Cell Research, 2015], led us to hypothesize that the observed 
chromatin rearrangements could be mediated by the lack of H3K18ub seated by 
UHRF1 RING domain. In the absence of a commercial specific antibodies against 
H3K18ub that allowed us to perform a ChIP in our regions of interest, we designed 
and produced a monoclonal antibody against the H3K18ub. Unfortunately, its 
validation is still ongoing due to the complexity of ubiquitination profile of histone 
H3. In the meanwhile, we performed a SILAC LC-MS/MS on RKO cells after siUHRF1, 
in order to better elucidate the involvement of UHRF1 in specific ubiquitination of 
histone tails. In fact, this technique gave us the advantage to analyze in a quantitative 
single mass-spectrometry analysis, a pool of histone peptide, mixed in ration 1 to 1, 
labeled with different non-radioactive stable isotopes, allowing to discriminate the 
different samples loaded in mass-spectrometry (i.e. control = Light isotopes; siUHRF1 
= Heavy isotopes). In this experiment, we analyzed, for the first time, the role of 
UHRF1 in the modulation of histone ubiquitinations in a tumor cell line. Intriguingly, 
our finding demonstrated that UHRF1 KD induced a decrease in the mono-
ubiquitination of H3K23 and a surprisingly strong increase in H3K18 bi-ubiquitination 
(bona fide relying on the molecular weight of the analyzed peptides that did not 
shown any other detectable ubiquitination). Interestingly we identified two different 
pool of peptides, mono-ubiquitinated in K18 or mono-ubiquitinated in K23, 
belonging to a different pool of histones H3 that migrate, as expected, in the same 
molecular weight (25KDa) during electrophoresis, and that present reciprocal 
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unmodified residues, respectively K23un in K18ub peptides and K18un in K23ub 
peptides. These two peptides showed an important decrement in ubiquitination, 
upon UHRF1 silencing, mostly in K23ub. On the contrary we identified another 
mono-ubiquitination in K18 peptides, belonging to a third different pool of histones 
H3, that present acetylation in K23 and an increased ubiquitination after UHRF1 
depletion. Even if these data seem to not agree to the previous publications in ESC 
[Qin W., et al; Cell Research, 2015] these data are the first one to be performed in 
tumor cell line setting, without the overexpression of any form of UHRF1 or histones. 
Further, our finding in RKO cells, delineated a more complex pool of histone H3 
ubiquitination related to UHRF1 E3-ligase activity, in accordance with other recent 
publication [Harrison JS, et al.; eLife, 2016] [Nishiyama A, et al.; Nature, 2013], 
assigning increased importance to RING domain functionality in the correct 
maintenance of DNA methylation patterns. 
 
Relying on these finding and on previously reported role of RING domain in 
heterochromatic formation [Karagianni P, et al.; Mol. Cell. Biol., 2008], we 
formulated the third fundamental pivot of the molecular model that comes out from 
this PhD Thesis: the mono-ubiquitinations of histone H3 are fundamental for a 
correct localization and functionality of DNMT1, leading to a strong de-methylation, 
upon UHRF1 KD, as described before, and are also crucial in the maintenance of a 
repressed heterochromatic state of chromatin (H3K9me3 rich), leading to a severe 
chromatin rearrangement, after UHRF1 depletion, toward a more open 
transcriptional accessibility (H3K4me3 enrichment). In fact, it is well-know that 
acetylation in the same residues of histone H3 (e.g. K18, K23) are key marks of 
euchromatic active state of chromatin [Wang Z, et al.; Nat Genet., 2008]. Thus, we 
speculated that the decrement observed in these ubiquitinated residues after UHRF1 
KD could be toward acetylation of the same residues. Unfortunately, this remains 
intricate to detect either in the band corresponding to the molecular weight of total 
H3 (15KDa) due to the coexistence of several modification (e.g. K4me3, K9me3, other 
acetylations, etc.) resulting in the impossibility to identify uniquely the 
corresponding peptides, and even in bulk analysis where the amount of gained 
acetylated K18 of K23 are undetectable and indistinguishable among the other more 
represented acetylations. On the contrary, the intriguing finding of a strong increase 
of H3K18 bi-ubiquitination, upon UHRF1 KD, prompted us to speculate the incoming 
of other E3-ubiquitin ligases that polyubiquitinate histone H3. It is well-know that 
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UHRF1 stability is regulated through a fine-tuning of poly-ubiquitination and de-
ubiquitination processes, mediated respectively by proteins belonging to SCF 
complex (i.e. β-TrCP1 and β-TrCP2) [Chen H et al.; Mol. Cell. Biol.; 2013], and de-
ubiquitinase USP7 [Qin W., et al; J. Cell. Biochem., 2011] [Zhang ZM, et al.; Cell 
Reports, 2015]. USP7 is also known to be part of PRC1 together with other several 
RING domain proteins (e.g. RING1A/B) [Aranda S, et al.; Sci. Adv., 2015]. PRC2, firmly 
present in the analyzed promoter regions as described before, is known to interact 
with CUL4–DDB1 ubiquitin ligase [Higa LA, et al.; Nature Cell Biol., 2006], reported to 
ubiquitinated histone H3 and H4 [Wang H, et al.; Molecular Cell, 2006]. All these 
intriguing observations prompted us to speculate that after UHRF1 depletion occurs 
a disequilibrium among all these ubiquitinase/de-ubiquitinase complexes leading to 
the increased bi-ubiquitinated H3K18ub observed. 
 
Ultimately, we investigated the genome-wide relationship between the strong DNA 
de-methylation observed and the possible alteration of the transcriptome. 
Interestingly, the Ingenuity Pathway Analysis (IPA) showed that UHRF1 silencing 
interferes with several important pathways, among others cell proliferation, cell 
growth, DNA damage and DNA repair, cell cycle and Wnt signaling. In particular, we 
observed a coherent induction of the crucial actors of TFGβ signaling pathway (e.g. 
TFGβ, SMAD2/3). Noteworthy, the overexpression of these factors is generally 
related to CIN-CRCs and is associated with loss of heterozygosity (LOH) at 
chromosome locus 18q [Grady WM, and Carethers JM; Gastroenterology, 2008]. 
However, we observed a downregulation in some genes belonging to the cell cycle 
ontological cluster, in agreement with our previous reports [Babbio F, et al.; 
Oncogene, 2012]. Then, since we observed an modest percentage of DM CpGs 
located in the promoter regions (16%) and in body of genes (Exon 15% + Intron 35%), 
we coupled the DM CpGs with the DE transcripts. Our studies demonstrated that, 
even if there is cluster of genes that are hypo-methylated and up-regulated, these 
transcripts represented only the 3% of the hypo-methylated CpGs identified. This 
finding, perfectly consistent with our previous observation about not re-expression 
of CDH1, MLH1 and LINE-1 loci, suggested that, in RKO cells, only few specific loci are 
directly regulated by DNA methylation status and UHRF1 overexpression. We might 
speculate that these regions present a different chromatin profile, less regulated by 
PRC2, mostly controlled by UHRF1/DNMT1 and therefore more prone to the re-
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expression after UHRF1 KD. However, further studies are necessary to elucidate the 
role of UHRF1 and DNA methylation in the regulation of these specific loci/genes. 
 
Recapitulating the three main pivots that sustain the molecular model proposed in 
this PhD Thesis: (i) UHRF1 depletion and subsequent de-localization of DNMT1 
induces a strong decrement in DNA methylation, however that might reinforce the 
binging of DNMT3B, due to its peculiar ability to recognize the residual methylation 
in CpGs contained in nucleosome rich regions, leading to a not complete de-
methylation; (ii) UHRF1 depletion results in a severe chromatin rearrangement, 
inducing a decrease of H3K9me3 and an increase of H3K4me3, however the presence 
of PRC2 (H3K27me3) drives a compensative-repressive mechanism, that, acting in 
concert with DNMT3B, leads to the not re-expression of CDH1, MLH1 and LINE-1 loci; 
(iii) the H3 mono-ubiquitinations by UHRF1 RING domain are fundamental for the 
correct localization/functionality of DNMT1, leading to a strong de-methylation, 
upon UHRF1 KD, moreover, lack of UHRF1 lead to a severe chromatin rearrangement 
toward a more open transcriptional accessibility, probably due to the disruption of 
the axis UHRF1-H3ub-DNMT1-HMTs. 
 
More broadly, we demonstrated that UHRF1 is deeply involved in the regulation of 
DNA methylation both in CRC human samples and CRC-derived cell lines. Moreover, 
UHRF1 plays a significant role in the establishment of heterochromatic epigenetic 
signatures modulating directly (ubiquitination) or indirectly (HMTs, HDAC1 
recruitment) the histone PTMs profile. 
In conclusion, since we observed in RKO MSI-CRC-derived cells that UHRF1 correlates 
positively with an overall DNA hypermethylation and a precise heterochromatin 
stability, in accord with literature [Karagianni P, et al.; Mol. Cell. Biol., 2008] [Papait 
R, et al.; Mol. Biol. Cell., 2008], we speculate that the better prognosis correlated 
with MSI-CRC model, could reside in the UHRF1-high levels that result in a sort of 
protective condition for the genome integrity, maintaining the global DNA 
methylation level closer to the normal mucosae, and probably counteracting the 
hyper-methylation of TSGs. Further studies, upon UHRF1 depletion, delineating 
genomic stability, by loss of heterozygosity (LOH) analysis [Matsuzaki K, et al.; Clin. 
Cancer Res., 2005], and epigenomic stability, by loss of imprinting (LOI) analysis 
[Holm TM, et al.; Cancer Cell, 2005], will clarify the proposed role of UHRF1 as a gate-
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6.3. PhD experience abroad 
During my PhD experience, I had the opportunity to spend two long periods, both of 
them in the Laboratory of Prof. Kirsten Sadler Edepli. The first one (December 2015) 
was spent at Mont Sinai Medical School of Medicine (New York City, USA) and the 
second one (August 2016 – December 2016) was spent at New York University Abu 
Dhabi (Abu Dhabi, UAE). The goal of these experiences was to better evaluate the 
role of the phosphorylation of S661 in altering RING-mediated E3 ubiquitination 
activity. In particular, we were interested to better investigate the effects of this 
phosphorylation on UHRF1 localization, and on the ability of UHRF1 to mono-
ubiquitinate the H3K18 and poly-ubiquitinate DNMT1. Regarding the role of the 
allosteric regulations and/or PTMs of UHRF1, several publications report that 
different factors/PTMs are able to interact with the polybasic region (PBR) of UHRF1. 
It has been reported that the phosphatidylinositol 5-phosphate (PI5P) [Gelato K. A. 
et al.;, Molecular Cell, 2014] and the deubiquitinase USP7 [Qin W., et al; Journal of 
Cellular Biochemistry, 2011] [Zhang et al.;, Cell Reports, 2015] interact with PBR (641-
657 AA of UHRF1 isoform 1 or 656-669 AA of isoform 2). Furthermore, it has been 
shown that UHRF1 can interact with a novel lncRNA, named UPAT, over-expressed 
in cancer, that protect UHRF1 from ubiquitination on K650 (K663 of isoform 2) by β-
TrCP1 and β-TrCP2, and its degradation via proteasome [Taniue K. et al.; PNAS, 
2015]. 
Concerning PTMs, UHRF1 can be phosphorylated on different serines, nearby the 
polybasic region (PBR). Serine 639 (in UHRF1 isoform 1, S652 in isoform 2) was 
reported to be phosphorylated by CDK1/cyclin B in M phase, regulating UHRF1 
stability via proteasomal degradation, and impairing the physical association with 
the deubiquitinase USP7 [Ma H. et al.; PNAS, 2012]. It has been shown that Serine 
661 (S674 on UHRF1 isoform 2) is phosphorylated by the cyclin A/CDK2 during S 
phase, both in vitro and in vivo. This phosphorylation is essential for embryonic 
development, and alters the localization of UHRF1 under some conditions [J. Chu et 
al.; Molecular Biology of the Cell, 2012]. Moreover, it has been observed that the 
UHRF1-S661A (non-phosphorylatable residue) is less stable and constitutively 
nuclear in contrast with wild-type UHRF1, which is more stable and localizes both in 
the nucleus and the cytoplasm. Furthermore, it has been shown that UHRF1p661 




Recently it has been reported a novel molecular function of UHRF1pS661, that seems 
to be alternative or additional to its well-known role in heterochromatin formation 
and epigenetics. In fact, this phosphorylation confers the ability to be recruited by 
BRAC1 (via BRCT domain) to Double Strand Breaks (DSBs). Thus, UHRF1pS661, by the 
RING domain, mediates K63-linked poly-ubiquitination of RIF1, promoting its 
dissociation from DSBs, inactivating RIF1 focus formation, and facilitating the switch 
of DSBs repair pathway choice from NHEJ to HR (mediated by the BRCA1 pathway) 
[Zhang H. et al.; Nature Communications, 2015]. 
In this recent publication, the authors claimed that this important novel function in 
DSBs repair, related to UHRF1 and its E3 ligase activity, is separate or alternative 
from its role in mono-ubiquitination of H3. Nevertheless, the authors showed only a 
WB on H3 unmodified, evaluating the presence of signal corresponding to expected 
molecular weight of the mono-ubiquitination of H3 (23KDa). 
Basing on this knowledge, the first experiments were performed in order to 
investigate if phospho-S661 could impair/alter the RING-domain activity. We 
performed a histone acid extract in HeLa cells overexpressing alternatively UHRF1, 
UHRF1-S661E, DNMT1 and UHRF1-S661A (Figure F4, bottom panel, on left). 
Unfortunately, it seems that the overexpression of the plasmids had some toxicity in 
HeLa cell (morphological alteration, data not shown), altering the profile of H3K18ub 
in strange ways. Furthermore, the presence of endogenous UHRF1 (Wild Type), 
although present in low amount in HeLa cells could be able to act normally, causing 
the failure of this experiment. 
For all these reasons, we planned to design the specific point mutation (on serine 
661) using the genome editing tool CRISP/Cas9 in RKO cells. At the moment, I have 
performed the first steps in this direction, during my second experience abroad, and 
I will continue in the next months within the newly established collaboration 
between our two Labs. 
 
